For Ca in excitable and non-excitable cells 2+ Low-affinity red fluorescent indicators for imaging

By developing a new low-affinity fluorescent Ca2+ indicator, the imaging artifacts and phototoxicity problems in Ca2+ detection in the prior art are solved, and accurate detection of Ca2+ changes in cardiac cells and redshift light excitation is achieved, which is suitable for cardiomyocytes and Mitochondria application.

CN112055716BActive Publication Date: 2024-11-01THE GOVERNORS OF THE UNIV OF ALBERTA +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980028715.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-03-02
Filing Date
2019-03-01
Publication Date
2024-11-01
Estimated Expiration
2039-03-01

AI Technical Summary

Technical Problem

When the existing low-affinity Ca2+ indicators detect Ca2+ changes in heart cells, they are prone to imaging artifacts due to cell movement, and high-energy ultraviolet light excitation is related to phototoxicity, making it difficult to achieve physiologically related Ca2+ change detection.

Method used

A low-affinity fluorescent Ca2+ indicator including LAR-GECO1.5, LAR-GECO2, LAR-GECO3, LAR-GECO4, LAREX-GECO1, LAREX-GECO2, LAREX-GECO3, LAREX-GECO4 and other low-affinity fluorescent Ca2+ indicator was developed, and by changing the calcium regulation The interaction between protein and the light chain kinase of chicken samsaki myosin, regulates the dissociation constant of indicators, and adopts a non-cyclic arrangement topology and specific mutagenesis strategy to reduce the affinity for Ca2+, which is suitable for redshift light excitation , reduce phototoxicity.

Benefits of technology

Accurate detection of Ca2+ changes in cardiac cells, reduce phototoxicity, and improve the ability to visualize Ca2+ kinetic changes, especially in cardiomyocytes and mitochondria, providing a longer wavelength photoexcitation option, reducing movement artifacts and phototoxicity risks.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112055716B_ABST
    Figure CN112055716B_ABST
Patent Text Reader

Abstract

The present invention provides a red-shifted low affinity Ca 2+ Indicator and detection of cell Ca 2+ The method comprises the following steps: obtaining a sample; and detecting SR Ca level changes by contacting the sample with an indicator. 2+ or mitochondrial Ca 2+ Level changes using red-shifted low-affinity Ca 2+ Indicator to detect SR Ca 2+ or mitochondrial Ca 2+ Changes in levels.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention generally relates to low affinity fluorescent Ca 2+ An indicator that can target the endoplasmic reticulum, sarcoplasmic reticulum and / or mitochondria. Background Art

[0002] In cardiac cells, the sarcoplasmic reticulum (SR) is responsible for Ca 2+ Induced Ca 2+ release (CICR), which makes the voltage-dependent Ca 2+ Entry triggers myofilament contraction. Because contraction is associated with SR motion, ratiometric (as opposed to intensiometric) imaging methods must be used to correct for motion artifacts.

[0003] Calcium ions (Ca) in subcellular compartments such as mitochondria, endoplasmic reticulum (ER), and SR 2+ ) concentration ranges from low micromolar to high millimolar. 2+ concentration compartment, optimized for detection of cytoplasmic Ca 2+ (usually 0.1 μM to 10 μM) the fluorescent indicator becomes saturated and becomes sensitive to Ca 2+ To address this problem, a great deal of research effort has been devoted to developing low-affinity Ca 2+ Indicators, including genetically encoded fluorescent proteins (FPs). In contrast to indicators based on synthetic dyes, FP-based indicators are delivered to cells along with their corresponding DNA coding sequences and may include other sequences that are expressed in specific tissues or targeted to specific subcellular compartments.

[0004] Early examples of low-affinity indicators include D1ER and D4cpv, which are based on the Ca2+ / - relationship between the cyan FP and the yellow FP. 2+ Fluorescence resonance energy transfer (FRET, FRET-based indicators are ratiometric in nature, providing quantitative measurements that are not affected by imaging artifacts due to organelle or cell movement. Indicators engineered from a single FP tend to be intensity-based and generally provide larger signal changes. The first low-affinity Ca2+ targeting ER based on a single FP was 2+ The indicator is CatchER TM Recently, a number of low-affinity GCaMP-type Ca 2+ Indicators, which consist of a circularly permutated FP fused to calmodulin (CaM) and a Ca2+ The binding form is the peptide composition. These indicators include CEPIA TM 、LAR-GECO TM and ER-GCaMP TM Another ratiometric, low-affinity, single-FP-based Ca 2+ The indicator is GEM-CEPIA1er TM , but it requires excitation with high-energy UV light (≤400nm), which is often associated with increased phototoxicity and autofluorescence.

[0005] It may be desirable to use indicators that are excitable with longer wavelength (ie, more red-shifted or >400 nm) light, as longer wavelength (ie, more red-shifted or >400 nm) light is generally associated with reduced phototoxicity and autofluorescence.

[0006] This background information is provided for the purpose of providing known information believed by the applicant to be potentially relevant to the present invention. It is not necessarily intended, and should not be construed, as an admission that any of the foregoing information constitutes prior art to the present invention. Summary of the invention

[0007] In one aspect, the invention may include a method for detecting Ca in a cell. 2+ A level change method, the method comprising:

[0008] (a) obtaining a sample comprising cells engineered to express one or more low-affinity Ca 2+ An indicator selected from the group consisting of LAR-GECO1.5, LAR-GECO2, LAR-GECO3, LAR-GECO4, LAREX-GECO1, LAREX-GECO2, LAREX-GECO3 and LAREX-GECO4, or a polypeptide having an amino acid sequence substantially similar to any of the foregoing;

[0009] (b) exposing the cells to an excitation light; and

[0010] (c) Detection of ER, SR, and / or mitochondrial Ca by visualization or imaging of cells 2+ Changes in levels.

[0011] In another aspect, the present invention may comprise a low affinity fluorescent Ca selected from the group consisting of 2+Polypeptide: LAR-GECO1.5, LAR-GECO2 and LAR-GECO3, LAR-GECO4, LAREX-GECO1, LAREX-GECO2, LAREX-GECO3 and LAREX-GECO4, or a polypeptide having an amino acid sequence substantially similar to any of the foregoing. In some embodiments, the amino acid sequence of the polypeptide may be one of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16 or 18.

[0012] In some embodiments, the polypeptide may comprise a mutation selected from the group consisting of I54A, I330M, and D327N / I330M / D363N. 2+ K d It may be greater than 20 μM, or preferably about 60 μM.

[0013] In another aspect, the present invention may include encoding a low affinity fluorescent Ca 2+ In some embodiments, the polynucleotide may comprise a nucleic acid sequence selected from the group consisting of:

[0014] (a) SEQ ID NO: 3, 5, 7, 9, 11, 13, 15 or 17;

[0015] (b) having at least 90% sequence identity to one of SEQ ID NOs: 3, 5, 7, 9, 11, 13, 15 or 17 and encoding a fluorescent Ca 2+ The indicator nucleic acid sequence, the fluorescent Ca 2+ Indicator for Ca 2+ K d greater than 20 μM or alternatively about 60 μM, excluding SEQ ID NO: 1;

[0016] (c) Encoding fluorescent Ca 2+ The indicator nucleic acid sequence, the fluorescent Ca 2+ The indicator comprises the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16 or 18; and

[0017] (d) Encoding fluorescent Ca 2+ The indicator nucleic acid sequence, the fluorescent Ca 2+ The indicator has at least 90% sequence identity with the amino acid sequence of SEQ ID NO: 4, 6, 8, 10, 12, 14, 16 or 18 (but not including SEQ ID NO: 2), and the fluorescent Ca 2+ The indicator is greater than 20 μM or alternatively about 60 μM.

[0018] In some embodiments, the polynucleotide comprises a mutation encoding an amino acid mutation selected from the group consisting of: I54A, I330M, and D327N / I330M / D363N.

[0019] In other aspects, the present invention may include a vector or a host cell comprising a polynucleotide sequence of the present invention. In some embodiments, the host cell is a cardiomyocyte. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Reference is made to the accompanying drawings which illustrate in detail several aspects of the present invention by way of example and not limitation, in which:

[0021] Figure 1 Shows low affinity for Ca 2+ Schematic strategy for indicator engineering.

[0022] Figure 2 Amino acid sequence alignment of LAR-GECO1, LAR-GECO1.5, LAR-GECO2, LAR-GECO3 and LAR-GECO4 is shown.

[0023] Figure 3 The amino acid sequence alignment of LAREX-GECO1, LAREX-GECO2, LAREX-GECO3 and LAREX-GECO4 is shown.

[0024] Figure 4 Shows the effect of Ca 2+ Intensive and ratiometric red Ca with a wide range of affinities 2+ Indicator.

[0025] Figure 5 In vitro characterization of LAR-GECO is shown. (A, D, G, and J) Excitation and emission spectra of LAR-GECO1.5 (A), LAR-GECO2 (D), LAR-GECO3 (G), and LAR-GECO4 (J). (B, E, H, and K) 2+ state (dashed line) and bound Ca 2+ Absorption and emission spectra of LARGECO1.5 (B), LAR-GECO2 (E), LAR-GECO3 (H) and LAR-GECO4 (K) under the state (solid line). (C, F, I, L) Relationship between the fluorescence intensity of LAR-GECO1.5 (C), LAR-GECO2 (F), LAR-GECO3 (I) and LAR-GECO4 (L) and pH.

[0026] Figure 6In vitro characterization of LAREX-GECO is shown. (A, D, G, and J) Excitation and emission spectra of LAREX-GECO1 (A), LAREX-GECO2 (D), LAREX-GECO3 (G), and LAREX-GECO4 (J). (B, E, H, and K) 2+ state (dashed line) and bound Ca 2+ Absorption and emission spectra of LAREX-GECO1 (B), LAREX-GECO2 (E), LAREX-GECO3 (H), and LAREXGECO4 (K) under the state (solid line). (C, F, I, and L) Relationship between the fluorescence intensity of LAREX-GECO1 (C), LAREX-GECO2 (F), LAREX-GECO3 (I), and LAREX-GECO4 (L) and pH.

[0027] Figure 7 ER-LAREX-GECO4 expressed in HeLa cells (n=7) can detect SR Ca2+ after histamine stimulation. 2+ Kinetics. ΔR / R=(R 初始 -R) / R 初始 *100%, where R is the ratio of the emission intensity under 470nm excitation to the emission intensity under 595nm excitation, R 初始 is the initial ratio. The gray bar indicates the application of 20 μM histamine.

[0028] Figure 8 The immortalized mouse atrial HL1 cell line showed low affinity Ca 2+ Comparison of indicators. (A) Expression of ER-LAR-GECO3 and ER-LAR-GECO4 in HL1 cells. Live cell images are pseudo-colored red on the left (images), and fixed images of ER-LAR-GECO3 and ER-LAR-GECO4 taken by confocal microscopy are shown in grayscale on the right. ER-LAR-GECO3 (B), ER-LAR-GECO4 (C), and ER-LAREX-GECO4 (DF) were observed to express ER / SRCa in response to caffeine stimulation. 2+Changes. Ratiometric stimulation of ER-LAREX-GECO4 was achieved by laser irradiation at 488 nm (D) and 594 nm (E). (F) ΔR / R0 curve calculated from (D) and (E). (G) Performance comparison of ER-LAR-GECO4 (n=21), ER-LAR-GECO3 (n=14), ER-LAREX-GECO2 (n=8), ER-LAREX-GECO1 (n=7), ER-LAREX-GECO4 (n=14), ER-LAREX-GECO3 (n=8), and R-CEPIAer (n=15). For intensity-type indicators, ΔF SR =(F 初始 -F 咖啡因 ) / F 初始 *100%, where F is the fluorescence intensity, F 初始 is the initial strength, F 咖啡因 is the strength immediately after adding caffeine. For ratio indicators, ΔR SR =(R 初始 -R 咖啡因 ) / R 初始 *100%, where R is the ratio of the emission intensity under 488nm excitation to the emission intensity under 594nm excitation, R 初始 is the initial ratio, R 咖啡因 This is the ratio immediately after adding caffeine.

[0029] Fig. 9 Shown is the performance comparison of ER-LAR-GECO and ER-LAREX-GECO in human embryonic stem cell derived cardiomyocytes (hES-CM) relative to G-CEPIAer benchmark.HES-CM is co-transfected with ER-LAR-GECO, ER-LAREX-GECO or R-CEPIAer and G-CEPIAer.The representative emission signal (vertical pair of figure) of each reporter pair of single cells is obtained simultaneously by dual view system (Dual View system).Some cells (i.e. R-CEPIA-G-CEPIA pairs) have experienced spontaneous oscillation of simultaneous contraction and relaxation.Inset shows the time delay of 0.8 to 1 minute of hES-CM expressing G-CEPIAer and R-CEPIAer.Gray bar shows the addition of caffeine.

[0030] Fig.10 Cytosolic Ca in iPSC-derived cardiomyocytes (iPSC-CMs) is shown. 2+ and SR Ca 2+Observation. Cells were co-transfected with G-GECO and ER-LAREX-GECO3 to observe their spontaneous activity and response to caffeine stimulation (grey bars). G-GECO was irradiated with a 488 nm laser. ER-LAREX-GECO3 was stimulated by 488 nm and 594 nm laser irradiation. Two types of responses were observed. (A and B) A large initial response to caffeine administration was observed in one group of cells, but spontaneous SR depletion and subsequent Ca 2+ (C) The second panel of cells shows spontaneous SR emptying and cytoplasmic Ca oscillations detectable in iPS-CMs before (blue arrows) and after caffeine administration. 2+ The left side shows the intensity of each emission channel, and the right side shows the processed ratio data set.

[0031] Fig.11 Figure 3 shows that caffeine-stimulated cytosolic Ca2+ was observed in HL1 cells in response to G-GECO1. 2+ and ER / SR Ca 2+ Changes, where G-GECO1 is (A) ER-LAR-GECO4 and (B) ER-LAR-GECO3. The thick grey line represents the average response of the G-GECO1 cytoplasmic emission (F / Fo(Cyto)) with the corresponding left y-axis as the ratio bar. The thick black line represents the average response of the SR target red-shifted indicator ((F / Fo(SR)) with the right y-axis as the ratio bar. Individual cell responses are shown with thin grey lines. Caffeine administration is represented by grey bars.

[0032] Fig.12 Figure 2 shows the characterization of ER / SR storage in human embryonic stem cell derived cardiomyocytes (hES-CM) by ratiometric measurements using ER-LAREX-GECO3. ER-LAREX-GECO3 was excited by laser irradiation at 488 nm and 594 nm. Caffeine depletes SR storage, Ca 2+ will refill slowly, with small Ca 2+ oscillations, which are more clearly observed in the ratio (black, iii) curve.

[0033] Fig.13 Single wavelength excitation demonstrated to observe cytoplasmic Ca in hES-CM 2+ (G-GECO) and ER / SR Ca 2+(ER-LAREX-GECO4). (A) G-GECO and ER-LAREX-GECO4 excited by blue light are shown. ER-LAREX-GECO4 was further imaged by confocal microscopy (grayscale image on the right), showing the typical disordered arrangement of SR in these cell types. (B) Time-lapse of hES-CM response to caffeine treatment. A 480nm LED was used to excite G-GECO and ER-LAREX-GECO4. The dual-view system observed the signals simultaneously at 10Hz. The gray bar shows the administration of caffeine.

[0034] Fig.14 Shown that ER / SR Ca in iPSC-CMs can be monitored by ratiometric measurements using ER-LAREX-GECO3 under electrical pacing 2+ Kinetics. (A) Time-lapse of iPSC-CMs expressing ER-LAREX-GECO3 in response to electrical pacing at 0.5 Hz and 1.0 Hz. ER-LAREX-GECO3 was excited by LED illumination at 470 nm (i) and 595 nm (ii) to acquire ratiometric imaging. Signals were observed at 25 Hz. (B) F / F0 was calculated from (A), where F is the fluorescence intensity and F0 is the resting intensity. R is the ratio of F / F0 (ex 470) / F / F0 (ex 595), shown as black line (iii). Cells were paced by C-Pace EP (ION OPTIX) and voltage conditions were set to 15 V. Grey boxes indicate the time slots during which cells were stimulated with electrodes.

[0035] Fig.15 Immunofluorescence characterization of stem cell-derived cardiomyocytes (displaying a typical essentially rounded appearance rather than an elongated appearance) is shown, with immunofluorescence staining for the sarcomeric components troponin-T and α-actinin to confirm cardiomyocyte identity. Within these mixed populations, a small fraction of cells were binucleated, with some areas having a distinctly more organized SERCA staining, possibly indicative of Fig.13 Cell maturation compared to A. Scale bar, 10 μm. Zoomed images taken from main images as shown.

[0036] Fig.16 The expression of mt-LAREX-GECO4 in HeLa cells for ratiometric observation of calcium dynamics in mitochondria is shown. (A) Subcellular distribution of mt-LAREX-GECO4. The ratio bar represents 10 μm. (B) A large amount of Ca in mitochondria was detected in response to 20 μM histamine. 2+ Inflow. mt-LAREX-GECO4 was excited by LED emission at 470 nm and 595 nm. The grey bar indicates the application of histamine. DETAILED DESCRIPTION

[0037] The specific embodiments and drawings set forth below are intended as descriptions of various embodiments of the present invention, and are not intended to represent the only embodiments contemplated by the inventors. For the purpose of providing a comprehensive understanding of the present invention, the specific embodiments include specific details, however, the claimed invention may not be limited to these specific details.

[0038] Embodiments of the present invention can provide novel red-shifted low-affinity Ca 2+ Toolbox of indicators and polynucleotide sequences encoding such indicators having a useful dynamic range and Ca 2+ Affinity. The Ca 2+ Indicators can be selectively expressed and retained in organelles by fusing organelle-specific targeting sequences to the indicator molecule. Thus, these indicators can target high concentrations of Ca 2+ The SR can be stored in cultured cardiomyocytes or mitochondria and can be imaged alone or in combination with other indicators, allowing the direct visualization of important aspects of disease-related biology that have hitherto been typically studied indirectly.

[0039] In some embodiments, the present invention may comprise a protein derived from LAR-GECO1 (K d =24 μM) [SEQ ID NO: 2] intensity-type red fluorescent low affinity Ca 2+ Indicator. To engineer an intense red fluorescent low affinity Ca 2+ The indicator is activated by altering the interaction between calmodulin (CaM) and a short peptide of chicken gizzard myosin light chain kinase (RS20) and by modifying CaM's response to Ca 2+ affinity to regulate the dissociation constant of LAR-GECO1. Figure 1 , a different strategy was used to synthesize the red fluorescent low affinity Ca 2+ Indicator.

[0040] The first strategy involved modifying the indicator topology by fusing the N-terminus of RS20 to the C-terminus of CaM, while restoring the original non-circular arrangement (ncp) FP end (i.e., the “camgaroo” topology, so called because the indicator pocket carries a smaller partner). The structure of the circular arrangement (cp) R-GECO1 (PDB ID 4I2Y) is used here to represent the LAR-GECO1 variant, as Figure 1 Left side of A. Red fluorescent protein domain attached to Ca 2+ The Ca binding domain 2+ The binding domain consists of calmodulin (orange cylinder) and RS20 (grey cylinder). 2+ Represented as purple balls. Figure 1The non-circular arrangement (ncp) LAR-GECO1.5 [SEQ ID NO: 4] is shown to the right of A. The blue line shows the cp linker or the CaM-RS20 linker for the ncp topology.

[0041] Alternative strategies involve site-specific mutagenesis, for example, alanine scanning of the CaM-RS20 interface to weaken this interaction, 2+ Incorporation of mutations outside the binding site or in the Ca 2+ Binding site incorporation mutations. Figure 1 B exemplarily shows examples of strategies 2, 3 and 4. On the left, the LAR-GECO1.5 structure is shown, highlighting the target residues for strategies 2 to 4. On the right, the primary sequences of RS20 and CaM, highlighting the target residues as shown in the LAR-GECO1.5 structure.

[0042] based on Figure 1 Strategy 1, shown, converts LAR-GECO1 to an ncp topology to obtain LAR-GECO1.5, in which CaM and RS20 are connected by a Gly-Gly-Gly-Gly-Ser-Val-Asp linker, in which the FP terminus is restored. Without being limited to theory, this altered topology may have two possible advantages. The first advantage is that the linker between RS20 and CaM can be engineered to potentially change the effective K d The second advantage is that, due to the direct connection between RS20 and CaM, they are less likely to interact with endogenous proteins in the ER or SR.

[0043] LAR-GECO1.5 has a similar Ca content to LAR-GECO1 2+ affinity while maintaining the affinity for Ca 2+ The fluorescence response of was 7.4-fold higher, indicating that the NCP topology does not adversely affect this function. Figure 4 The fluorescence intensity normalized to free Ca in buffer (10 mM MOPS, 100 mM KCl, pH 7.2) is shown. 2+ The curve for LAR-GECO1.5 is essentially the same as that for LAR-GECO1. Thus, the NCP topology is retained for low-affinity Ca 2+ Design and engineering of indicators.

[0044] Using LAR-GECO1.5 as a template, strategies 2, 3, and 4 (and / or their combinations) were investigated to generate gene variants and express them in the context of E. coli colonies. Fluorescence imaging of colonies was used to identify brightly fluorescent clones, which were picked, cultured, and assayed for Ca 2+This process allowed the identification of 2+ Three exemplary indicators of reduced affinity.

[0045] In the alanine scanning construct, the indicator with the Ile54Ala mutation (called LAR-GECO2 [SEQ ID NO: 6]) showed Ca 2+ K d At 60 μM, it was found that 2+ The fluorescence increased 5.7-fold after binding. Based on the Ile330Met mutation, K d 110 μM and for Ca 2+ Based on the mutations of Asp327Asn, Ile330Met and Asp363Asn, K d 540 μM and for Ca 2+ The fluorescence response of the indicator was 13 times that of the indicator (named LAR-GECO4 [SEQ ID NO: 10]).

[0046] The low affinity of LAR-GECO2, LAR-GECO3, and LAR-GECO4 is associated with the identified mutations, and therefore, some embodiments of the invention may include variant polypeptides that differ in other domains but retain the same or similar function and retain more than one of these mutations.

[0047] Genetic fusions of all indicators to the ER targeting and retention sequences and expression in HeLa cells exhibited the expected ER localization pattern and bright red fluorescence. Figure 7 ER-LAREX-GECO4 expressed in HeLa cells can detect ER / SR Ca2+ after histamine stimulation. 2+ dynamics.

[0048] Table 1: In vitro characterization of the LAR-GECO series

[0049]

[0050]

[0051] Therefore, as shown in Table 1, LAR-GECO2, LAR-GECO3, and LAR-GECO4 are red fluorescent Ca 2+ indicators, which are intensive and have lower affinity than their parent indicator LAR-GECO1.

[0052] In another aspect, the present invention includes ratiometric low-affinity red GECOs. In some embodiments, these indicators have ratiometric properties that reduce sensitivity to motion, improve quantitative measurements, and enable single wavelength excitation using dual-color imaging strategies. Thus, in some embodiments, the present invention includes at least four novel ratiometric low-affinity red GECOs that are sensitive to Ca 2+ The affinity of the peptide was 146 μM to 1023 μM and is referred to herein as LAREX-GECO.

[0053] These novel new indicators are derived from REX-GECO1, a previously reported ratiometric red Ca 2+ Indicators engineered into ncp topology. The same mutations used to engineer LAR-GECO3 and LAR-GECO4 described above were then introduced to generate the novel indicators LAREX-GECO1 [SEQ ID NO: 12] and LAREX-GECO2 [SEQ ID NO: 14]. Figure 4 Panel B shows the normalized excitation ratios versus free Ca in buffer (10 mM MOPS, 100 mM KCl, pH 7.2). 2+ The relationship between the excitation ratio and the fluorescence intensity at 480nm and 580nm respectively. d Ca 2+ The dissociation constant of REX-GECO1 (K d 240 nM), the new indicators (called LAREX-GECO1 and LAREX-GECO2) provided significantly reduced Ca 2+ Affinities were 146 μM and 1023 μM, respectively.

[0054] In other embodiments, LAREX-GECO derivatives are further generated in which the CaM portion of REX-GECO1 is replaced by the CaM portion of R-CEPIA1er, a previously reported strong low-affinity red Ca 2+ The resulting novel indicator (called LAREX-GECO3 [SEQ ID NO: 16]) showed that Ca 2+ K d The K of LAREX-GECO3 was 564 μM and the dynamic range was 23-fold. Conversion of the LAREX-GECO3 protein to the ncp topology generated another new indicator (termed LAREX-GECO4 [SEQ ID NO:

[18] ) with a similar K d The kinetic range was 18-fold.

[0055] Table 2 summarizes the characterization of LAREX-GECO.

[0056] Table 2: Overview of ratio indicators

[0057]

[0058] A summary of the calcium affinities of the indicators is provided in Table 3. The characterization of these indicators is described below.

[0059] Table 3: Ca 2+ Overview of indicators

[0060] name <![CDATA[K d (μM)]]> Topology LAR-GECO1 24 cp LAR-GECO1.5 24 ncp LAR-GECO2 60 ncp LAR-GECO3 110 ncp LAR-GECO4 540 ncp LAREX-GECO1 146 ncp LAREX-GECO2 1023 ncp LAREX-GECO3 564 cp LAREX-GECO4 593 ncp

[0061] Observation of Ca in cardiomyocytes 2+ dynamics

[0062] In heart muscle cells (called cardiomyocytes), contraction and relaxation require the cyclical release and reuptake of Ca 2+ , so Ca 2+ It is a key regulator of contraction. Normally, cytoplasmic concentrations range from the diastolic range (~0.1 μM free Ca 2+ ) into a systolic range one order of magnitude higher (~1 μM free Ca 2+ ). Due to intracellular Ca 2+ Buffering effect is significant, requiring about 100 μM total Ca 2+ Most of the Ca required 2+ The Ca in the SR is only a small part of the cell volume, so the Ca 2+ The concentration of Ca is much higher than that in the cytoplasm. As a result, due to the lack of low affinity Ca 2+ Indicator, it is difficult to observe Ca in SR 2+ For this reason, cytoplasmic Ca2+ activity in response to caffeine-induced SR emptying in the presence or absence of various chemical inhibitors is often used. 2+ indirect measurement of .

[0063] Low affinity Ca 2+ Fluo-5N(K d = 97 μM) has been used to visualize SR Ca in isolated permeabilized adult human ventricular myocytes 2+ However, specific SR loading without cytoplasmic contamination may be difficult to achieve and, as an intensity-based indicator, it may be susceptible to motion artifacts. Stem cell-derived cardiomyocytes lack the typical spatial T-tubule / SR structure seen in ventricular myocytes, making it impossible to identify erroneous cytoplasmic signals based on positional information.

[0064] In one embodiment, the indicators of the present invention can alleviate these challenges and provide SR Ca 2+The results show that cardiomyocytes show physiological beat-to-beat variations in myocardial activity, which can be directly visualized in cell culture as well as in stem cell-derived cardiomyocytes.

[0065] Visualization of SR Ca in cell culture 2+ Physiological changes

[0066] Various models are used in cardiovascular research. In one aspect of the invention, a cell culture of a stable immortalized cell line, referred to as the HL1 cell line, derived from mouse atrial cardiomyocytes, is used as a model.

[0067] Reference Figure 8 (Figures A, B, and C) and Fig.11 , ER-LAR-GECO3 and ER-LAR-GECO4 were evaluated by co-expressing cytoplasmic G-GECO1 in the HL1 cell line. In response to the addition of 10 mM caffeine, cytosolic Ca 2+ Increased signaling can be accompanied by ER / SR Ca 2+ Signal reduction.

[0068] refer to Figure 8 In Figures D, E, and F, ratiometric imaging of ER-LAREX-GECO4 was obtained by dividing the emission intensity at 488 nm by the emission intensity at 594 nm.

[0069] refer to Figure 8 Figure G shows the intensity or ratiometric responses (ΔF) of various indicators of the present invention after stimulation of HL1 cell line with caffeine. SR or ΔR SR ) showed that ER-LAREX-GECO4 and ER-LAREX-GECO3 had the largest signal changes (-72.9+ / -15.2% and -76.0+ / -16.1%, respectively). The present invention also provides in vitro characterization, demonstrating that ER-LAREX-GECO4 (kinetic range 18×, K d =593 μM) and ER-LAREX-GECO3 (dynamic range 23×, K d =564 μM) for the detection of Ca2+ in SR cardiomyocytes during the cyclic relaxation (~1000 μM to 1500 μM) to contraction (~300 μM to 600 μM) 2+ Variations have a large dynamic range and optimal K d value.

[0070] Visualization of SR Ca in stem cells 2+ Physiological changes

[0071] In another aspect, the indicators described herein can provide SR Ca in cardiomyocytes derived from, for example, human embryonic stem cells (hES) or human induced pluripotent stem cells (hiPSC). 2+ Such stem cells can be used as models for genetic heart diseases or as in vitro drug toxicity and drug screening platforms.

[0072] refer to Fig. 9 , the green low affinity indicator G-CEPIAer (reported kinetic range 4.7×, K d =672 μM) was used as an internal standard to minimize the effects of cell phenotypic variability and immaturity. In stem cell-derived cardiomyocytes, the indicators described herein were compared with the green low-affinity indicator G-CEPIAer. In addition to the SR Ca response to caffeine administration, 2+ In addition to depletion, the present invention can also visualize physiological beat-by-beat SR emptying.

[0073] From the intensity curve, the response of the red indicator (ΔF SR ) can be divided by the pairwise ΔF of G-CEPIAer SR , R was generated in the same cell for comparison 红 / 绿 Ratio (ΔF of red channel SR ΔF of G-CEPIAer SR ). ER-LAREX-GECO3(R 红 / 绿 =1.03+ / -0.08), which seems to be equivalent to G-CEPIAer. In this system, ER-LAREX-GECO3 and ER-LAREX-GECO4 (R 红 / 绿 =0.71+ / -0.02) seem to outperform R-CEPIAer (R 红 / 绿 =0.60+ / -0.06), which is consistent with the results obtained in the HL1 cultured cell line and the in vitro data. Isolated comparisons between cells (e.g. using G-CEPIAer curves alone) can reveal significant heterogeneity in individual responses, which may be a weakness of current in vitro stem cell-derived cardiomyocyte models.

[0074] Ratiometric LAREX-GECO3 and LAREX-GECO4 indicators offer advantages in in vitro systems and can be further characterized in stem cell models.

[0075] An advantage of ratiometric indicators over some intensity-based indicators is that they self-correct for cell motion. This is a particular problem with caffeine stimulation, because emptying of the SR induces larger motions than the regular oscillatory contractions and relaxations of cultured cardiomyocytes. Such ratiometric imaging allows the observation of spontaneous beat-to-beat Ca 2+ Release and reuptake. Fig.12 , after caffeine was administered to deplete SR Ca 2+ After concentration, Ca can be easily detected 2+ Oscillations during reuptake into SR.

[0076] On the other hand, Fig.14 As shown, ER-LAREX-GECO3 can also be used to detect the beat-by-beat Ca in iPSC-CMs under electrical pacing. 2+ Concentration changes.

[0077] like Figure 6 As shown, the ratiometric indicator has a Ca-dependent 2+ The stimulation (such as Fig.12 , which appears to capture most of the information about SR emptying and refilling), embodiments of the invention may include single-wavelength dual-color imaging using G-GECO1 and ER-LAREX-GECO4 in stem cell-derived cardiomyocytes (e.g. Fig.13 ). This avoids the need to switch illumination sources and is therefore a strategy to use for high frame rate imaging or where prolonged observations may be required in some cases.

[0078] Reference Fig. 9 , since physiological SR Ca may not be detected in all cells expressing G-CEPIA 2+ depletion, even though they all clearly contracted, the present invention may allow the use of co-expression of G-GECO and ER-LAREX-GECO3 in iPSC cardiomyocytes to observe cytosolic Ca 2+ Ratio measurement of SR Ca 2+ release, such as Fig.10 shown.

[0079] refer to Fig.10 Figure B shows that although some cells appear to be activated by the initial caffeine-induced SR Ca 2+ Depletion and cytoplasmic Ca 2 + There is an initial correlation between accumulation, but subsequent oscillations can be seen to be unconnected. However, ref. Fig.10 Figure C shows that other cells differentiated from the same stem cell have shown spontaneous cytosolic Ca 2+ Transients and Ca2+ in adjacent SR 2+ fluctuations, indicating that SR stores of physiological Ca before caffeine treatment 2+ Release contributes to cytosolic Ca 2+ After caffeine administration, these cells showed cytoplasmic Ca 2+ The amplitude of transient recovery is related to SR Ca 2+The correlation of the gradual recovery of cytoplasmic content and the persistent association of cytoplasmic and SR signals during subsequent oscillations.

[0080] This cell-autonomous behavior (using cytoplasmic Ca alone) 2+ curves may not be identifiable) may reflect different stages of in vitro maturation. Supporting this point is that, for example, Fig.13 As shown, a small fraction of stem cell-derived cardiomyocytes appear to develop components such as SERCA TM ) higher-order structure, which may be related to the observed correlation of excitation and contraction.

[0081] Observation of Ca in mitochondria 2+ dynamics

[0082] Calcium signaling is known to play an important role in regulating mitochondrial function. 2+ ) overload is one of the pro-apoptotic ways to induce mitochondrial swelling. Therefore, real-time monitoring of Ca2+ in a way that predicts the cell state or response to different stimuli is very important. 2+ The dynamics will be of interest. However, like the ER / SR, mitochondria also contain high concentrations of Ca 2+ , therefore, there are relatively few variants optimized for studying calcium signaling in mitochondria. The low-affinity indicators of the present invention may provide a solution. Fig.16 The expression of mt-LAREX-GECO4 in HeLa cells was used for ratiometric observation of calcium dynamics in mitochondria. (A) Subcellular distribution of mt-LAREX-GECO4. The ratio bar represents 10 μm. (B) A large amount of Ca2+ in mitochondria was detected in response to 20 μM histamine. 2+ Inflow. mt-LAREX-GECO4 was excited by LED emission at 470 nm and 595 nm. The grey bar indicates the application of histamine.

[0083] Peptide and nucleotide sequences

[0084] Aspects of the present invention include fluorescent polypeptides as described herein having the amino acid sequences shown or substantially similar amino acid sequences. Substantially similar amino acid sequences will have at least some levels of sequence identity, having the same or similar functions. It is well known to those skilled in the art that many levels of sequence identity can be used to identify polypeptides, wherein such polypeptides have the same or similar functions or activities. Percentage identities of more than 90% (i.e., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%) may be useful.

[0085] In an embodiment of the present invention, if the polypeptides have similar fluorescence and are sensitive to Ca 2+ With low affinity (K dGreater than 20 μM, more preferably greater than about 60 μM), they will have the same or similar functions. However, it should be understood that the progenitor fluorescent polypeptides LAR-GECO1 and REX-GECO1 are not included as substantially similar sequences, nor are any nucleic acid sequences encoding progenitor fluorescent polypeptides.

[0086] As used herein, "nucleic acid" refers to a polynucleotide, including a single-stranded or double-stranded polymer of deoxyribonucleotides or ribonucleotide bases. Nucleic acids may also include fragments and modified nucleotides. Therefore, the terms "polynucleotide", "nucleic acid sequence", "nucleotide sequence" or "nucleic acid fragment" are used interchangeably, which are single-stranded or double-stranded polymers of RNA or DNA, optionally containing synthetic non-natural or altered nucleotide bases. Nucleotides (usually present in the form of 5'-monophosphates) are represented by the following single letters: "A" represents adenylic acid or deoxyadenylic acid (RNA or DNA, respectively), "C" represents cytidylic acid or deoxycytidylic acid, "G" represents guanylic acid or deoxyguanosine, "U" represents uracil, "T" represents deoxythymidylic acid, "R" represents purine (A or G), "Y" represents pyrimidine (C or T), "K" represents G or T, "H" represents A or C or T, "I" represents inosine, and "N" represents any nucleotide.

[0087] The terms "homology", "homologous", "substantially similar" and "substantially corresponding" are used interchangeably herein. They refer to nucleic acid fragments in which the change of one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate gene expression or produce a certain phenotype. These terms also refer to modifications of nucleic acid fragments, for example, the deletion or insertion of one or more nucleotides that does not substantially change the functional properties of the resulting nucleic acid fragment relative to the unmodified initial fragment. Therefore, as will be appreciated by those skilled in the art, the present invention encompasses more than just the specific exemplary sequences.

[0088] The present invention may also include nucleic acid sequences encoding polypeptides having amino acid sequences as described herein or substantially similar amino acid sequences, as well as substantially similar nucleic acid sequences. Substantially similar nucleic acid sequences may have more than 90% (i.e., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%) sequence identity.

[0089] In the context of nucleic acid or polypeptide sequences, "sequence identity" or "identity" refers to the same nucleic acid bases or amino acid residues in two sequences when aligned over a specified comparison window for maximum correspondence. Therefore, "percentage of sequence identity" refers to a value determined by comparing two optimally aligned sequences in a comparison window; wherein, for optimal alignment of two sequences, the portion of the polynucleotide or polypeptide sequence in the comparison window may contain additions or deletions (i.e., gaps) compared to the reference sequence (which does not contain additions or deletions). The number of matching sites is generated by determining the number of sites where the same nucleic acid base or amino acid residue appears in the two sequences, dividing the number of matching sites by the total number of sites in the comparison window, calculating the percentage, and then multiplying the result by 100 to generate the percentage of sequence identity, thereby calculating the percentage. These identities can be determined by those skilled in the art, including using any of the programs described herein.

[0090] Sequence alignments and percent identity or percent similarity calculations can be determined using a variety of comparison methods designed to detect homologous sequences, including but not limited to MegAlign of the LASERGENE bioinformatics computing suite. TM Program (DNASTAR Inc., Madison, Wisconsin). In the context of this application, it is understood that in the case of analysis using sequence analysis software, unless otherwise specified, the results of the analysis will be based on the "default values" of the program used. As used herein, "default values" will refer to any set of values ​​or parameters that are initially loaded by the software when it is first initialized.

[0091] The "Clustal V alignment method" corresponds to the method labeled Clustal V (described in Higgins and Sharp, CABIOS, 5:151-153 (1989); Higgins, DG et al. (1992) Comput. Appl. Biosci. 8:189-191) and available in the MegAlign library of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wisconsin). TMThe default parameters for pairwise alignment and calculation of percent identity of protein sequences using the Clustal method are KTUPLE=1, GAP PENALTY=3, WINDOW=5, and DIAGONALS SAVED=5. For nucleic acids, these parameters are KTUPLE=2, GAP PENALTY=5, WINDOW=4, and DIAGONALS SAVED=4. After aligning the sequences using the Clustal V program, the "percent identity" can be obtained by viewing the "sequence distance" table in the same program.

[0092] The "BLASTN alignment method" is an algorithm provided by the National Center for Biotechnology Information (NCBI) for comparing nucleotide sequences using default parameters.

[0093] In addition, those skilled in the art recognize that substantially similar nucleic acid sequences encompassed by the present invention are also defined by their ability to hybridize (under moderately stringent conditions, e.g., 0.5xSSC, 0.1% SDS, 60°C) with sequences described herein or with any portion of the nucleotide sequences disclosed herein (and which are functionally equivalent to any nucleic acid sequence disclosed herein). Stringent conditions can be adjusted to screen for moderately similar fragments (e.g., homologous sequences from distantly related organisms) to highly similar fragments (e.g., genes that replicate functional enzymes of closely related organisms). Post-hybridization washing requires stringent conditions.

[0094] The term "selectively hybridizes" includes hybridization of a nucleic acid sequence to a specific nucleic acid target sequence to a detectably higher degree (e.g., at least 2-fold above background) under stringent hybridization conditions compared to hybridization to non-target nucleic acid sequences, substantially to the exclusion of "non-target nucleic acids." Selectively hybridizing sequences typically have at least about 80% sequence identity, or 85%, 90%, or 95% sequence identity, up to and including 100% sequence identity (i.e., fully complementary) to each other.

[0095] The term "stringent conditions" or "stringent hybridization conditions" includes conditions under which a probe will selectively hybridize to its target sequence. Stringent conditions depend on the sequence and will vary in different situations. By controlling the stringency of the hybridization and / or washing conditions, a target sequence that is 100% complementary to the probe can be identified (homologous detection). Alternatively, stringent conditions can be adjusted to allow for some mismatching in the sequence, thereby detecting lower similarities (heterologous detection). Typically, the probe is less than about 1000 nucleotides in length, and optionally less than 500 nucleotides in length.

[0096] Typically, stringent conditions will be those with a salt concentration of less than about 1.5 M Na ions, typically about 0.01 M to 1.0 M Na ion concentration (or other salts), at pH 7.0 to 8.3, at a temperature of at least about 30°C for short probes (e.g., 10 to 50 nucleotides), and at least about 60°C for long probes (e.g., greater than 50 nucleotides). Stringent conditions may also be achieved by adding destabilizing agents such as formamide. Exemplary low stringency conditions include hybridization at 37°C with a buffer solution of 30% to 35% formamide, 1 M NaCl, 1% SDS (sodium dodecyl sulfate), and washing at 50°C to 55°C with 1x SSC to 2x SSC (20xSSC = 3.0 M NaCl / 0.3 M trisodium citrate). Exemplary moderate stringency conditions include hybridization with 40 to 45% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 0.5× SSC to 1× SSC at 55° C. to 60° C. Exemplary high stringency conditions include hybridization with 50% formamide, 1 M NaCl, 1% SDS at 37° C., and a wash in 0.1× SSC at 60° C. to 65° C.

[0097] Typically, specificity is a function of post-hybridization washing, with the key factors being the ionic strength and temperature of the final wash solution. For DNA-DNA hybrids, T can be approximated by the equation of Meinkoth et al. (Anal. Biochem. 138: 267-284 (1984)). m :T m =81.5°C+16.6(log M)+0.41(%GC)-0.61(%formamide)-500 / L; wherein M is the molar concentration of monovalent cations, %GC is the percentage of guanosine nucleotides and cytosine nucleotides in DNA, %formamide is the percentage of formamide in the hybridization solution, and L is the length of the hybrid in base pairs. m is the temperature (under defined ionic strength and pH) at which 50% of the complementary target sequence hybridizes to a perfectly matched probe. For every 1% mismatch, T m decrease by about 1°C; therefore, T m , hybridization and / or washing conditions to hybridize to sequences of desired identity. For example, if sequences with >90% identity are sought, T m Generally, stringent conditions are selected to be higher than the thermal melting point (T) of the specific sequence and its complement at a defined ionic strength and pH. m However, high stringency conditions can be used at temperatures below the melting point (T m ) is 1°C, 2°C, 3°C or 4°C lower than the hybridization and / or washing; moderate stringency conditions can be used at a temperature below the thermal melting point (T mHybridization and / or washing are performed at 6°C, 7°C, 8°C, 9°C or 10°C lower than the thermal melting point (T m ) and hybridization and / or washing is performed at 11°C, 12°C, 13°C, 14°C, 15°C or 20°C. Using this equation, hybridization and wash compositions and the desired T m , the skilled artisan will understand that variations in the stringency of hybridization and / or wash solutions are inherently described. m If the temperature is less than 45°C (aqueous solution) or 32°C (formamide solution), it is preferred to increase the SSC concentration so that a higher temperature can be used. A detailed guide to nucleic acid hybridization can be found in Tijssen, Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization with Nucleic Acid Probes, Part I, Chapter 2, "Overview of Hybridization Principles and Nucleic Acid Probe Assay Strategies", Elsevier, New York (1993); and Current Protocols in Molecular Biology, Chapter 2, Ausubel et al., eds., Greene Publishing and Wiley-Interscience, New York (1995). Hybridization and / or washing conditions can be applied for at least 10 minutes, 30 minutes, 60 minutes, 90 minutes, 120 minutes, or 240 minutes.

[0098] Example

[0099] Embodiments of the present invention are described with reference to the following examples. These examples are provided for illustrative purposes only.

[0100] Example 1A: Engineering of LAR-GECO

[0101] pBAD / His B vector TM LAR-GECO1 (Life Technologies) was used as the initial template for assembling LAR-GECO1.5 (Strategy 1– Figure 1The development of LAR-GECO1 is described in Wu et al., Red fluorescent genetically encoded Ca2+ indicators for use in mitochondria and endoplasmic reticulum, Biochem J. 2014 Nov 15; 464(1): 13-22, the entire contents of which are incorporated herein by reference (where permitted).

[0102] The N terminus of RS20 and the C terminus of CaM in LAR-GECO1 were linked by an amino acid sequence (GGGGSVD), and the initial ncp FP terminus was restored by overlap extension polymerase chain reaction (PCR). To explore strategies 2, 3, and 4 that led to the formation of LAR-GECO2, LAR-GECO3, and LAR-GECO4, the Quikchange Lightning Site-directed Mutagenesis Kit was used following the manufacturer's instructions. TM (Agilent) to introduce the point mutations listed in Table 4 into LAR-GECO1.5. Oligonucleotides containing specific mutations were designed with the aid of the Agilent online mutagenesis primer design program.

[0103] Table 4: Overview of mutations introduced for the engineered LAR indicator series

[0104]

[0105]

[0106] Example 1B: Engineering of LAREX-GECO

[0107] To engineer LAREX-GECO1 and LAREX-GECO2, REX-GECO1 was first converted to ncp topology in the pBAD / His B vector (Life Technologies) by overlap extension PCR as described above. Point mutations of LAR-GECO3 and LAR-GECO4 were then introduced into this ncp version of REX-GECO1 using the Quikchange Lightning Site-Directed Mutagenesis Kit (Agilent) as described above to make LAREX-GECO1 and LAREX-GECO2, respectively. To construct LAREX-GECO3, the CaM domain of REX-GECO1 was replaced with the CaM domain of R-CEPIA1er by overlap extension PCR. pCMV R-CEPIA1er TMFor Masamitsu Iino TM (Addgene plasmid #58216). LAREX-GECO4 was constructed by changing the topology of LAREX-GECO3 to ncp as described above. The sequences of all LAR-GECO and LAREX-GECO constructs were verified by sequencing.

[0108] To test the Ca of all LAR-GECO and LAREX-GECO variants 2+ Affinity, each variant in the pBAD / His B vector (Life Technologies) was electroporated into E. coli strain DH10B TM (Invitrogen). E. coli containing these variants were then cultured overnight at 37°C in 10 cm LB-agar dishes supplemented with 400 μg / mL ampicillin (Sigma) and 0.02% (wt / vol) L-arabinose (Alfa Aesar). These dishes were then placed at room temperature for 24 hours before imaging. During imaging, images of each dish were captured by illuminating the E. coli colonies using an excitation filter of 542 / 27 nm (for LAR-GECO variants) or both 438 / 24 nm and 542 / 27 nm (for LAREX-GECO variants) and an emission filter of 609 / 57 nm. Then, a single E. coli colony emitting red fluorescence for each variant was picked out and cultured overnight at 37°C in 4 mL of liquid LB supplemented with 100 μg / mL ampicillin and 0.02% (wt / vol) L-arabinose. The cells were then imaged by B-PER according to the manufacturer's instructions. TM (Pierce) extracted proteins from liquid LB cultures. The extracted protein solutions of each variant were then subjected to Ca 2+ Titration. In Ca 2+ In the titration, the extracted protein solution was added to 2+ Concentration of Ca 2+ Buffer. By mixing Ca 2+ Saturated buffer and Ca-free 2+ Buffer (30 mM MOPS, 100 mM KCl, 10 mM chelating agent, pH 7.2, with or without 10 mM Ca 2+ ), to prepare Ca 2+ / HEDTA buffer and Ca 2 + / NTA buffer to achieve 0 mM to 1.3 mM buffer Ca 2+ concentration. By using Safire2 TMFluorescence microplate reader (Tecan) was used to record the different Ca 2+ The fluorescence intensities of these variants were then compared to the Ca 2+ The concentrations were plotted and fitted with the Hill equation to calculate the effect of each variant on Ca 2+ The dissociation constant.

[0109] Example 2: In vitro characterization

[0110] To characterize LAR-GECO in detail, the protein was expressed and purified as described in Wu J, Liu L, Matsuda T, Zhao Y, Rebane A, Drobizhev M, et al., Improved orange and red Ca2+ indicators and photophysical considerations for optogenetic applications, ACS Chem Neurosci. 2013;4:963–972 (Wu et al., 2013). Spectroscopic measurements were performed in a solution containing 10 mM EGTA or 10 mM CaNTA, 30 mM MOPS, 100 mM KCl, pH 7.2. To determine the fluorescence quantum yield of LAR-GECO and LAREX-GECO, mCherry and LSS-mKate2 were used as standards. Measurements of Ca2+ have been described by Wu et al. (2013). 2+ The fluorescence quantum yield, extinction coefficient, pK a , K d For Ca 2+ Titration: Add purified protein to Ca 2+ / HEDTA buffer and Ca 2+ / NTA buffer and fluorescence measurements were performed as described above.

[0111] refer to Figure 5 In vitro characterization of LAR-GECO1.5, LAR-GECO2, LAR-GECO3, and LAR-GECO4 showed that all four ncp Ca 2+ The indicators have essentially the same spectral properties as their parent LAR-GECO1. In addition, these new LAR-GECOs can be used in the absence of Ca 2+ The state shows a similar single-phase dependence on pH. 2+ Upon binding, this dependence on pH changes from monophasic to biphasic, which is very similar to the pH dependence of LAR-GECO1.

[0112] refer to Figure 6The new LAREX-GECOs have very similar spectral properties to their progenitor REX-GECO1. In addition, these LAREX-GECOs show a pH-dependence profile similar to that of REX-GECO1, with the maximum Ca 2+ The dependent ratio changes occurred between pH 7 and 9.

[0113] Example 3: Plasmids for mammalian cell imaging

[0114] The GECO gene targeted to the ER was generated using primers containing the ER targeting sequence (MLLPVPLLLGLLGAAAD [SEQ ID NO: 19]) and the ER retention signal sequence (KDEL). TM and EcoRI TM The PCR product was digested with restriction enzymes (Thermo). The digested DNA fragment was ligated to the modified pcDNA3 plasmid previously digested with the same two enzymes. TM The plasmid was purified (Thermo) and then sequenced to verify the inserted gene.

[0115] Example 4: Cell culture conditions and transfection

[0116] For culturing the HL1 cell line, pre-coat flasks with gelatin / fibronectin at 37°C overnight. TM Cells were cultured in Claycomb medium (Sigma Aldrich 12103C (lot 8A0177) containing 10% fetal bovine serum, 1U / ml penicillin / streptomycin, 0.1mM norepinephrine, and 2mM L-glutamine) and split 1:3 when cells reached confluence. Cells were transfected with transfection reagent Lipofectamine 2000 (Invitrogen) for 48 hours before acquiring images.

[0117] Incubate in DMEM / F12 TM (Invitrogen), 20% Knockout Serum Replacer TM The OxF2 human embryonic stem cell line was cultured with mouse embryonic fibroblasts (MEFs) in ES medium containing 1 mM glutamine, 1% non-essential amino acids, 125 μM mercaptoethanol, 0.625% penicillin / streptomycin, and 4 ng / ml basic fibroblast growth factor (bFGF) (Peprotech). One week before differentiation, ES colonies were manually split and placed in mTeSR1 medium. TMGeltrex by Stemcell TM (Gibco) coated six-well plates.

[0118] Human iPSC-derived cardiomyocytes (Human iPSC-derived cardiomyocytes-male|ax2505 TM ) was purchased from Axol Bioscience. The cells were plated in two wells of a 6-well plate and cultured in Axol's Cardiomyocyte Maintenance Medium. TM The cells were cultured for 8 days to 80%-90% confluence. The cells were then re-plated on glass-bottomed culture dishes coated with fibronectin / gelatin (0.5% / 0.1%) and transfected using the transfection reagent Lipofectamine 2000 (Invitrogen). Tyrode's buffer was used for final observation.

[0119] HeLa cells were cultured in Dulbecco's modified Eagle medium (Sigma–Aldrich) containing 10% fetal bovine serum (Invitrogen) in homemade 35 mm glass-bottom culture dishes. Cells were transfected with CMV-mito-LAREX-GECO4, ER-LAREX-GECO3, and ER-LAREX-GECO4 using the transfection reagent Lipofectamine 2000 (Invitrogen).

[0120] Example 5: Differentiation of cardiomyocytes from human pluripotent stem cells

[0121] This protocol is based on the method reported in Lian X, Zhang J, Azarin SM, Zhu K, Hazeltine LB, Bao X, et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt / β-cateninsignaling under fully defined conditions, Nat Protoc. 2013; 8: 162–175. ES cell colonies were dissociated into single cells using Accutase and placed in a Geltrex-coated 6-well plate (0.5×10 610 μM) of mTeSR1 supplemented with the rock inhibitor Y27632 (10 μM) were placed in 6-well plates. On day 3, at 80% to 90% confluence, the medium was changed to RPMI / B27 (B27 supplement without insulin – Gibco) containing 12 μM GSK-3 inhibitor (CHIR 99021 Tocris TM After 24 hours, the medium was changed to remove CHIR. After 48 hours, half of the medium (1 ml) was aspirated from each well and replaced with fresh RPMI / B27 containing the wnt inhibitor IWP 2 at a final concentration of 5 μM. TM (Tocris). After 48 hours, IWP was removed, and after another 48 hours, the medium was replaced with RPMI+B27 containing insulin. TM (Gibco). The culture was maintained in this medium, which was changed twice a week. The cells were then re-plated on fibronectin / gelatin (0.5% / 0.1%) coated glass bottom culture dishes and transfected using the transfection reagent Lipofectamine 2000 (Invitrogen).

[0122] Example 6: Immunostaining to characterize hES-derived cardiomyocytes

[0123] The primary antibodies were mouse monoclonal anti-actinin (Sigma No. A7811), rabbit polyclonal anti-troponin I (abcam, ab47003) and mouse monoclonal anti-SERCA2 ATPase TM (ABR No. MA3-910). Secondary antibodies are Fab fragment anti-mouse 488 and anti-rabbit 568 TM (Molecular Probes). The procedure was as follows: fixation with 4% paraformaldehyde (10 min at room temperature), permeabilization and washing with 0.1% Triton x-100 in Tris-buffered saline (TBST), blocking with 2% BSA in TBST with 0.001% sodium azide (1 h at room temperature), primary antibody at 1:200 (2 h at room temperature), wash 3 times with TBST (5 min each wash), secondary antibody at 1:1000 (1 h at room temperature), wash 3 times with TBST (5 min each wash), dry coverslips, and mount on Vectorshield TM (Vector Laboratories). Fluorescence imaging was performed with a Leica SP5 confocal microscope using a 63x oil objective at 488 nm and 543 nm excitation.

[0124] Example 7: Live cell imaging conditions

[0125] For non-ratio imaging, a 60x objective (NA 1.42 TM , Olympus) and multi-wavelength LED light sources (OptoLED TM , CARIN) inverted microscope (IX81 TM , Olympus). Blue (470 nm) and green (550 nm) excitation were used to illuminate G-GECO or G-CEPIA and LAR-GECO, respectively. The GFP filter set (DS / FF02-485 / 20-25, T495lpxr dichroic mirror and ET525 / 50 emission filter) was used to observe the signal of G-GECO in HL1 cells. The RFP filter set (DS / FF01-560 / 25-25, T565lpxr dichroic mirror and ET620 / 60 emission filter) was used to observe the signal of LAR-GECO3 and LAR-GECO4 in HL1 cells. The quad-band filter set, including a quad-band bandpass filter (DS / FF01-387 / 485 / 559 / 649-25, Semrock), a dichroic quadrilateral beam splitter (DS / FF410 / 504 / 582 / 669-Di01-25x36 TM (Semrock) and quad-band bandpass transmit filters (DS / FF01-440 / 521 / 607 / 700-25 TM , Semrock) was used to simultaneously observe G-CEPIA and LAR-GECO or G-GECO and LAR-GECO in ES-CM. TM , Olympus) controlled dual view system (DC2 TM , Photometrics) to record the fluorescence signal, the system has a EM-CCD camera (ImagEM TM , Hamamatsu) for the green (520 / 30nm) and red (630 / 50nm) channels.

[0126] For ratiometric imaging of HL1 cells, ES-CMs, and iPS-CMs by LAREX-GECO, an inverted confocal microscope ZEISS LSM710 equipped with a 63× 1.40NA oil objective and a multi-argon ion laser was used. TM In HL1 cells, red fluorescence images and far-red signals of LAREX-GECO were detected in the wavelength ranges of 560nm-710nm and 630nm-720nm using 488nm excitation and 594nm excitation, respectively. 2+ and cytoplasmic Ca 2+Transients, green, red, and far-red signals were detected in the wavelength ranges of 492nm-540nm, 630nm-728nm, and 630-728nm using 488nm excitation and 594nm excitation, respectively.

[0127] In order to Figure 7 and Fig.16 ) and iPSC-CMs( Fig.14 ) for ratiometric imaging, using an inverted microscope (D1, Zeiss) equipped with a 63x objective (NA 1.4, Zeiss) and a multi-wavelength LED light source (pE-4000, CoolLED). Blue (470nm) and orange (595nm) excitation were used to illuminate the LAREX-GECO for ratiometric excitation. An RFP filter set (T590lpxr dichroic mirror and ET 590lp emission filter) was used for imaging of the LAREX. Fluorescence signals were recorded using a CMOS camera (ORCA-Flash4.0LT, HAMAMATSU) controlled by software (HC Image).

[0128] Example 8: Construction of CMV-mito-LAREX-GECO4 vector

[0129] LAREX-GECO4 was subcloned from pcDNA3-LAREX-GECO4 (without ER targeting and retention sequences) as follows: LAREX-GECO4 without ER targeting (MLLPVPLLLGLLGAAAD [SEQ ID NO: 19]) and retention sequence (KDEL) from pcDNA3-LAREX-GECO4 plasmid ligated with BamHI was amplified using PCR primers with a 5' BamHI linker (MT-BamHI-LAREX_GECO4-F) and a 3' HindIII linker (MT-HindIII-LAREX-GECO4-R), replacing the LAR-GECO1.2 fragment with HindIII-digested CMV-mito-LAR-GECO1.2 (Addgene #61245). A start codon (ATG) was added in place of the ER targeting sequence, and a stop codon (TAA) was added in place of the retention sequence.

[0130] The oligonucleotides used in the cloning step were MT-BamHI-LAREX_GECO4-F: 5'-GATCGGATCCAACCATGGTGAGCAAGGGCGAGGAGGAT-3' [SEQ ID NO: 20] and MT-HindIII-LAREX_GECO4-R: 5'-GATCAAGCTTTTACTTGTACAGCTCGTCCATGCC-3' [SEQ ID NO: 21].

[0131] Sequence Listing

[0132] The sequence listing associated with this application is submitted in electronic format via e-PCT, and its entire contents are incorporated herein by reference. The name of the text file containing the sequence listing is 55326-272-Mar1-2019.txt. The size of the text file is 48KB and the text file was created on March 1, 2019.

[0133] illustrate

[0134] The description of the present invention has been given for the purpose of illustration and description, but it is not intended to be exhaustive or to limit the invention to the disclosed form. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the present invention. The embodiments are selected and described to best explain the principles and practical applications of the present invention and to enable other persons of ordinary skill in the art to understand that various modifications may be made to the various embodiments of the present invention to be suitable for the intended specific use. To the extent that the following description is a specific embodiment or specific use of the present invention, it is intended to be illustrative only and not to limit the claimed invention.

[0135] The corresponding structures, materials, operations, and equivalents of all means or step plus function elements in the claims attached hereto are intended to include any structure, material, or operation for performing the function in combination with other elements as specifically claimed.

[0136] References in the specification to "one embodiment", "one example", etc. indicate that the described embodiment may include a particular aspect, feature, structure, or characteristic, but not every embodiment must include that aspect, feature, structure, or characteristic. Moreover, such phrases may, but do not necessarily, refer to the same embodiment referred to in other parts of the specification. In addition, when a particular aspect, feature, structure, or characteristic is described in conjunction with an embodiment, it is within the knowledge of those skilled in the art to combine, influence, or connect such aspect, feature, structure, or characteristic with other embodiments, whether or not such connection or combination is explicitly stated. In other words, any element or feature may be combined with other elements or features in any different embodiment unless there is an obvious or inherent incompatibility between the two, or they are specifically excluded.

[0137] It should also be noted that the claims may be written to exclude any optional elements. As such, this statement is intended to serve as a prior basis for the use of exclusive terms (e.g., "only," "only," etc.) or "negative" limitations associated with the recitation of claim elements. The terms "preferably," "preferred," "preferred," "optionally," "may," and similar terms are used to indicate that the referenced item, condition, or step is an optional (non-essential) feature of the present invention.

[0138] Unless the context clearly indicates otherwise, the singular forms "a", "an" and "the" include plural forms. The term "and / or" refers to any one, any combination of these items or all of the items associated with the term.

[0139] As will be appreciated by those skilled in the art, for any and all purposes, particularly in providing written descriptions, all ranges listed herein also encompass any and all possible subranges and combinations of subranges thereof, as well as individual values, particularly integer values, that make up the ranges. The ranges listed (e.g., weight percent or carbon base) include each specific value, integer, decimal, or identity within the range. Any listed range can be easily identified as fully described, and the same range can be decomposed into at least equal halves, thirds, quarters, fifths, or tenths. As non-limiting examples, any range described herein can be easily divided into a lower third, a middle third, and an upper third, etc.

[0140] As will be further understood by one skilled in the art, all ranges described herein and all language, such as "up to," "at least," "greater than," "less than," "exceeding," "above," etc., include the recited numbers and these terms refer to ranges that can then be divided into the above sub-ranges. Sequence Listing <110> The Governors of the University of Alberta <120> Low-affinity red fluorescent indicator for Ca2+ imaging in excitable and non-excitable cells <130> 55326.272 PCT <160> twenty one <170> SIPOSequenceListing 1.0 <210> 1 <211> 1251 <212> DNA <213> Homo sapiens <400> 1 atggtcgact cttcacgtcg taagtggaat aaggcaggtc acgcatggag agctataggt 60 cggctgagct cacccgtggt ttccgagcgg atgtaccccg aggacggagc cctgaagagc 120 gagatcaaga aggggctgag gctgaaggac ggcggccact acgccgccga ggtcaagacc 180 acctacaagg ccaagaagcc cgtgcagctg cccggcgcct acgtcgtcga catcaagttg 240 gacatcgtgt cccacaacga ggactacacc atcgtggaac agtgcgaacg cgccgagggc 300 cgccactcca ccggcggcat ggacgagctg tacaagggag gtacaggcgg gagtctggtg 360 agcaagggcg aggaggataa catggccatc atcaaggagt tcatgcgctt caaggtgcac 420 atggagggct ccgtgaacgg ccacgagttc gagatcgagg gcgagggcga gggccgcccc 480 tacgaggcctttcagaccgc taagctgaag gtgaccaagg gtggccccct gcccttcgcc 540 tgggacatcc tgtcccctca gttcatgtac ggctccaagg cctacattaa gcacccagcc 600 gacatccccg actacttcaa gctgtccttc cccgagggct tcaggtggga gcgcgtgatg 660 aacttcgagg acggcggcat tattcacgtt aaccaggact cctccctgca ggacggcgta 720 ttcatctaca aggtgaagct gcgcggcacc aacttccccc ccgacggccc cgtaatgcag 780 aagaagacca tgggctggga ggctacgcgc gaccaactga ctgaagagca gatcgcagaa 840 tttaaagagg cttctccct atttgacaag gacggggatg ggacgataac aaccaaggag 900 ctggggacgg tgatgcggtc tctggggcag aaccccacag aagcagagct gcaggacatg 960 atcagtgaag tagatgccga cggtgacggc acattcgact tccctgagtt cctgacgatg 1020 atggcaagaa aaatgaatta cacagacagt gaagaggaaa ttagagaagc gttccgcgtg 1080 gcggataagg acggcaatgg ctacatcggc gcagcagagc ttcgccacgc gatgacagac 1140 attggagaga agttaacaga tgaggaggtt gatgaaatga tcagggtagc agacatcgat 1200 ggggatggtc aggtaaacta cgaagagttt gtacaaatga tgacagcgaa g 1251 <210> 2 <211> 417 <212> PRT <213> Homo sapiens <400> 2 Met Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His Ala Trp 1 5 10 15 Arg Ala Ile Gly Arg Leu Ser Ser Pro Val Val Ser Glu Arg Met Tyr 20 25 30 Pro Glu Asp Gly Ala Leu Lys Ser Glu Ile Lys Lys Gly Leu Arg Leu 35 40 45 Lys Asp Gly Gly His Tyr Ala Ala Glu Val Lys Thr Thr Tyr Lys Ala 50 55 60 Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Val Val Asp Ile Lys Leu 65 70 75 80 Asp Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Cys Glu 85 90 95 Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys 100 105 110 Gly Gly Thr Gly Gly Ser Leu Val Ser Lys Gly Glu Glu Asp Asn Met 115 120 125 Ala Ile Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser 130 135 140 Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro 145 150 155 160 Tyr Glu Ala Phe Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro 165 170 175 Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser 180 185 190 Lys Ala Tyr Ile Lys His Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu 195 200 205 Ser Phe Pro Glu Gly Phe Arg Trp Glu Arg Val Met Asn Phe Glu Asp 210 215 220 Gly Gly Ile Ile His Val Asn Gln Asp Ser Ser Leu Gln Asp Gly Val 225 230 235 240 Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly 245 250 255 Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Ala Thr Arg Asp Gln 260 265 270 Leu Thr Glu Glu Gln Ile Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe 275 280 285 Asp Lys Asp Gly Asp Gly Thr Ile Thr Thr Lys Glu Leu Gly Thr Val 290 295 300 Methionine Arginine Serine Leucine Glycine Glutamine Asparagine Proline Threonine Glutamic acid Alanine Glutamic acid Leucine Glutamine Aspartic acid Methionine 305 310 315 320 Isoleucine Serine Glutamic acid Valine Aspartic acid Alanine Aspartic acid Glycine Aspartic acid Glycine Threonine Phenylalanine Aspartic acid Phenylalanine Proline Glutamic acid 325 330 335 Phenylalanine Leucine Threonine Methionine Methionine Alanine Arginine Lysine Methionine Asparagine Tyrosine Threonine Aspartic acid Serine Glutamic acid Glutamic acid 340 345 350 Glutamic acid Isoleucine Arginine Glutamic acid Alanine Phenylalanine Arginine Valine Alanine Aspartic acid Lysine Aspartic acid Glycine Asparagine Glycine Tyrosine 355 360 365 Isoleucine Glycine Alanine Alanine Glutamic acid Leucine Arginine Histidine Alanine Methionine Threonine Aspartic acid Isoleucine Glycine Glutamic acid Lysine 370 375 380 Leucine Threonine Aspartic acid Glutamic acid Glutamic acid Valine Aspartic acid Glutamic acid Methionine Isoleucine Arginine Valine Alanine Aspartic acid Isoleucine Aspartic acid 385 390 395 400 Glycine Aspartic acid Glycine Glutamine Valine Asparagine Tyrosine Glutamic acid Glutamic acid Phenylalanine Valine Glutamine Methionine Methionine Threonine Alanine 405 410 415 Lysine <210> 3 <211> 1254 <212> DNA <213> Homo sapiens <400> 3 atggggagtc tggtgagcaa gggcgaggag gataacatgg ccatcatcaa ggagttcatg 60 cgcttcaagg tgcacatgga gggctccgtg aacggccacg agttcgagat cgagggcgag 120 ggcgagggcc gcccctacga ggcctttcag accgcttaagc tgaaggtgac caagggtggc 180 cccctgccct tcgcctggga catcctgtcc cctcagttca tgtacggctc caaggcctac 240 attaagcacc cagccgacat ccccgactac ttcaagctgt ccttccccga gggcttcagg 300 tgggagcgcg tgatgaactt cgaggacggc ggcattattc acgttaacca ggactctccc 360 ctgcaggacg gcgtattcat ctacaaggtg aagctgcgcg gcaccaactt cccccccgac 420 ggccccgtaa tgcagaagaa gaccatgggc tgggaggcta cgcgcgacca actgactgaa 480 gagcagatcg cagaatttaa agaggctttc tccctatttg aaaggacgg ggatgggacg 540 ataaaacca aggagctgggg gacggtgatg cggtctctgg ggcagaaccc cacagaagca 600 gaggctcagg acatgatcag tgaagtagat gccgacggtg acggcacatt cgacttccct 660 gagttcctga cgatgatggc aagaaaaatg aattacacag acagtgaaga ggaaattaga 720 gaagcgttcc gcgtggcgga tagagcagg aatggctaca tcggcgcagc agagcttcgc 780 cacgcgatga cagacattgg agagaagtta acagatgagg aggttgatga aatgatcagg 840 gtagcagaca tcgatgggga tggtcaggta aactacgaag agtttgtaca aatgatgaca 900 gcgaagggtg gcggaggttc tgtcgactca tcacgtcgta agtggaataa ggcaggtcac 960 gcatggagag ctataggtcg gctgagctca cccgtggttt ccgagcggat gtaccccgag 1020 gacggagccc tgaagagcga gatcaagaag gggctgaggc tgaaggacgg cggccactac 1080 gccgccgagg tcaagaccac ctacaaggcc aagaagcccg tgcagctgcc cggcgcctac 1140 gtcgtcgaca tcaagttgga catcgtgtcc cacaacgagg actacaccat cgtggaacag 1200 tgcgaacgcg ccgagggccg ccactccacc ggcggcatgg tcgggctgta caag 1254 <210> 4 <211> 418 <212> PRT <213> Homo sapiens <400> 4 Met Gly Ser Leu Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile 1 5 10 15 Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly 20 25 30 His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Ala 35 40 45 Phe Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe 50 55 60 Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr 65 70 75 80 Ile Lys His Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu Ser Phe Pro 85 90 95 Glu Gly Phe Arg Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Ile 100 105 110 Ile His Val Asn Gln Asp Ser Ser Leu Gln Asp Gly Val Phe Ile Tyr 115 120 125 Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly Pro Val Met 130 135 140 Gln Lys Lys Thr Met Gly Trp Glu Ala Thr Arg Asp Gln Leu Thr Glu 145 150 155 160 Glu Gln Ile Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe Asp Lys Asp 165 170 175 Gly Asp Gly Thr Ile Thr Thr Lys Glu Leu Gly Thr Val Met Arg Ser 180 185 190 Leu Gly Gln Asn Pro Thr Glu Ala Glu Leu Gln Asp Met Ile Ser Glu 195 200 205 Val Asp Ala Asp Gly Asp Gly Thr Phe Asp Phe Pro Glu Phe Leu Thr 210 215 220 Met Met Ala Arg Lys Met Asn Tyr Thr Asp Ser Glu Glu Glu Ile Arg 225 230 235 240 Glu Ala Phe Arg Val Ala Asp Lys Asp Gly Asn Gly Tyr Ile Gly Ala 245 250 255 Ala Glu Leu Arg His Ala Met Thr Asp Ile Gly Glu Lys Leu Thr Asp 260 265 270 Glu Glu Val Asp Glu Met Ile Arg Val Ala Asp Ile Asp Gly Asp Gly 275 280 285 Gln Val Asn Tyr Glu Glu Phe Val Gln Met Met Thr Ala Lys Gly Gly 290 295 300 Gly Gly Ser Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His 305 310 315 320 Ala Trp Arg Ala Ile Gly Arg Leu Ser Ser Pro Val Val Ser Glu Arg 325 330 335 Met Tyr Pro Glu Asp Gly Ala Leu Lys Ser Glu Ile Lys Lys Gly Leu 340 345 350 Arg Leu Lys Asp Gly Gly His Tyr Ala Ala Glu Val Lys Thr Thr Tyr 355 360 365 Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Val Val Asp Ile 370 375 380 Lys Leu Asp Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln 385 390 395 400 Cys Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Val Gly Leu 405 410 415 Tyr Lys <210> 5 <211> 1254 <212> DNA <213> Homo sapiens <400> 5 atggggagtc tggtgagcaa gggcgaggag gataacatgg ccatcatcaa ggagttcatg 60 cgcttcaagg tgcacatgga gggctccgtg aacggccacg agttcgagat cgagggcgag 120 ggcgagggcc gcccctacga ggcctttcag accgctaagc tgaaggtgac caagggtggc 180 cccctgccct tcgcctggga catcctgtcc cctcagttca tgtacggctc caaggcctac 240 attaagcacc cagccgacat ccccgactac ttcaagctgt ccttccccga gggcttcagg 300 tgggagcgcg tgatgaactt cgaggacggc ggcattattc acgttaacca ggactctccc 360 ctgcaggacg gcgtattcat ctacaaggtg aagctgcgcg gcaccaactt cccccccgac 420 ggccccgtaa tgcagaagaa gaccatgggc tgggaggcta cgcgcgacca actgactgaa 480 gagcagatcg cagaatttaa agaggctttc tccctatttg aaaggacgg ggatgggacg 540 ataaaacca aggagctgggg gacggtgatg cggtctctgg ggcagaaccc cacagaagca 600 gaggctcagg acatgatcag tgaagtagat gccgacggtg acggcacatt cgacttccct 660 gagttcctga cgatgatggc aagaaaaatg aattacacag acagtgaaga ggaaattaga 720 gaagcgttcc gcgtggcgga tagagcagg aatggctaca tcggcgcagc agagcttcgc 780 cacgcgatga cagacattgg agagaagtta acagatgagg aggttgat aatgatcagg 840 gtagcagaca tcgatggggga tggtcaggta aactacgaag agtttgtaca aatgatgaca 900 gcgaagggtg gcggaggttc tgtcgactca tcacgtcgta agtggataa ggcaggtcac 960 gcatggagag ctgcaggtcg gctgagctca cccgtggttt ccgagcggat gtaccccgag 1020 gacggagccc tgagagcga gatcagaag gggctgaggc tgaggacgg cggccactac 1080 gccgccgagg tcagaccac ctacaaggcc aagaagcccg tgcagctgcc cggcgcctac 1140 gtcgtcgaca tcaagttgga catcgtgtcc cacaacgagg actacaccat cgtggaacag 1200 tgcgaacgcg ccgaggggccg ccactccacc ggcggcatgg tcgggctgta caag 1254 <210> 6 <211> 418 <212> PRT <213> Homo sapiens <400> 6 Met Gly Ser Leu Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile 1 5 10 15 Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly 20 25 30 His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Ala 35 40 45 Phe Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe 50 55 60 Only Trp Asp Is Leu Served Pro Gln Phe Met Tyr Gly Served Lys Ala Tyr 65 70 75 80 Ile Lys His Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu Ser Phe Pro 85 90 95 Glu Gly Phe Arg Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Ile 100 105 110 Ile His Val Asn Gln Asp Ser Ser Leu Gln Asp Gly Val Phe Ile Tyr 115 120 125 Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly Pro Val Met 130 135 140 Gln Lys Lys Thr Met Gly Trp Glu Ala Thr Arg Asp Gln Leu Thr Glu 145 150 155 160 Glu Gln Ile Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe Asp Lys Asp 165 170 175 Gly Asp Gly Thr Ile Thr Thr Lys Glu Leu Gly Thr Val Met Arg Ser 180 185 190 Leu Gly Gln Asn Pro Thr Glu Ala Glu Leu Gln Asp Met Ile Ser Glu 195 200 205 Val Asp Ala Asp Gly Asp Gly Thr Phe Asp Phe Pro Glu Phe Leu Thr 210 215 220 Met Met Ala Arg Lys Met Asn Tyr Thr Asp Ser Glu Glu Glu Ile Arg 225 230 235 240 Glu Ala Phe Arg Val Ala Asp Lys Asp Gly Asn Gly Tyr Ile Gly Ala 245 250 255 Ala Glu Leu Arg His Ala Met Thr Asp Ile Gly Glu Lys Leu Thr Asp 260 265 270 Glu Glu Val Asp Glu Met Ile Arg Val Ala Asp Ile Asp Gly Asp Gly 275 280 285 Gln Val Asn Tyr Glu Glu Phe Val Gln Met Met Thr Ala Lys Gly Gly 290 295 300 Gly Gly Ser Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His 305 310 315 320 Ala Trp Arg Ala Ala Gly Arg Leu Ser Ser Pro Val Val Ser Glu Arg 325 330 335 Met Tyr Pro Glu Asp Gly Ala Leu Lys Ser Glu Ile Lys Lys Gly Leu 340 345 350 Arg Leu Lys Asp Gly Gly His Tyr Ala Ala Glu Val Lys Thr Thr Tyr 355 360 365 Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Val Val Asp Ile 370 375 380 Lys Leu Asp Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln 385 390 395 400 Cys Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Val Gly Leu 405 410 415 Tyr Lys <210> 7 <211> 1254 <212> DNA <213> Homo sapiens <400> 7 atggggagtc tggtgagcaa gggcgaggag gataacatgg ccatcatcaa ggagttcatg 60 cgcttcaagg tgcacatgga gggctccgtg aacggccacg agttcgagat cgagggcgag 120 ggcgagggcc gcccctacga ggcctttcag accgctaagc tgaaggtgac caagggtggc 180 cccctgccct tcgcctggga catcctgtcc cctcagttca tgtacggctc caaggcctac 240 attaagcacc cagccgacat ccccgactac ttcaagctgt ccttccccga gggcttcagg 300 tgggagcgcg tgatgaactt cgaggacggc ggcattattc acgttaacca ggactcctcc 360 ctgcaggacg gcgtattcat ctacaaggtg aagctgcgcg gcaccaactt cccccccgac 420 ggccccgtaa tgcagaagaa gaccatgggc tgggaggcta cgcgcgacca actgactgaa 480 gagcagatcg cagaatttaa agaggctttc tccctatttg acaaggacgg ggatgggacg 540 atgacaacca aggagctgggg gacggtgatg cggtctctgg ggcagaaccc cacagaagca 600 gaggctcagg acatgatcag tgaagtagat gccgacggtg acggcacatt cgacttccct 660 gagttcctga cgatgatggc aagaaaaatg aattacacag acagtgaaga ggaaattaga 720 gaagcgttcc gcgtggcgga tagagcagg aatggctaca tcggcgcagc agagcttcgc 780 cacgcgatga cagacattgg agagaagtta acagatgagg aggttgat aatgatcagg 840 gtagcagaca tcgatggggga tggtcaggta aactacgaag agtttgtaca aatgatgaca 900 gcgaagggtg gcggaggttc tgtcgactca tcacgtcgta agtggataa ggcaggtcac 960 gcatggagag ctataggtcg gctgagctca cccgtggttt ccgagcggat gtaccccgag 1020 gacgggagcc tgaagagcga ggaagaag ggggctgaggc tgaaggacgg cggccactac 1080 gccgccgagg tcaagaccac ctacaaggcc aagaagcccg tgcagctgcc cggcgcctac 1140 1200 tgcgaacgcg ccgagggccg ccactccacc ggcggcatgg tcgggctgta rubber 1254 <210> 8 <211> 418 <212> PRT <213> Homo sapiens <400> 8 Met Gly Ser Leu Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile 1 5 10 15 Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly 20 25 30 His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Ala 35 40 45 Phe Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe 50 55 60 Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr 65 70 75 80 Ile Lys His Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu Ser Phe Pro 85 90 95 Glu Gly Phe Arg Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Ile 100 105 110 Ile His Val Asn Gln Asp Ser Ser Leu Gln Asp Gly Val Phe Ile Tyr 115 120 125 Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly Pro Val Met 130 135 140 Gln Lys Lys Thr Met Gly Trp Glu Ala Thr Arg Asp Gln Leu Thr Glu 145 150 155 160 Glu Gln Ile Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe Asp Lys Asp 165 170 175 Gly Asp Gly Thr Met Thr Thr Lys Glu Leu Gly Thr Val Met Arg Ser 180 185 190 Leu Gly Gln Asn Pro Thr Glu Ala Glu Leu Gln Asp Met Ile Ser Glu 195 200 205 Val Asp Ala Asp Gly Asp Gly Thr Phe Asp Phe Pro Glu Phe Leu Thr 210 215 220 Met Met Ala Arg Lys Met Asn Tyr Thr Asp Ser Glu Glu Glu Ile Arg 225 230 235 240 Glu Ala Phe Arg Val Ala Asp Lys Asp Gly Asn Gly Tyr Ile Gly Ala 245 250 255 Ala Glu Leu Arg His Ala Met Thr Asp Ile Gly Glu Lys Leu Thr Asp 260 265 270 Glu Glu Val Asp Glu Met Ile Arg Val Ala Asp Ile Asp Gly Asp Gly 275 280 285 Gln Val Asn Tyr Glu Glu Phe Val Gln Met Met Thr Ala Lys Gly Gly 290 295 300 Gly Gly Ser Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His 305 310 315 320 Ala Trp Arg Ala Ile Gly Arg Leu Ser Ser Pro Val Val Ser Glu Arg 325 330 335 Met Tyr Pro Glu Asp Gly Ala Leu Lys Ser Glu Ile Lys Lys Gly Leu 340 345 350 Arg Leu Lys Asp Gly Gly His Tyr Ala Ala Glu Val Lys Thr Thr Tyr 355 360 365 Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Val Val Asp Ile 370 375 380 Lys Leu Asp Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln 385 390 395 400 Cys Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Val Gly Leu 405 410 415 Tyr Lys <210> 9 <211> 1254 <212> DNA <213> Homo sapiens <400> 9 atggggagtc tggtgagcaa gggcgaggag gataacatgg ccatcatcaa ggagttcatg 60 cgcttcaagg tgcacatgga gggctccgtg aacggccacg agttcgagat cgagggcgag 120 ggcgagggcc gcccctacga ggcctttcag accgcttaagc tgaaggtgac caagggtggc 180 cccctgccct tcgcctggga catcctgtcc cctcagttca tgtacggctc caaggcctac 240 attaagcacc cagccgacat ccccgactac ttcaagctgt ccttccccga gggcttcagg 300 tgggagcgcg tgatgaactt cgaggacggc ggcattattc acgttaacca ggactctccc 360 ctgcaggacg gcgtattcat ctacaaggtg aagctgcgcg gcaccaactt cccccccgac 420 ggccccgtaa tgcagaagaa gaccatgggc tgggaggcta cgcgcgacca actgactgaa 480 540 atgacaacca aggagctgggg gacggtgatg cggtctctgg ggcagaaccc cacagaagca 600 gagctgcagg acatgatcag tgaagtagat gccgacggta acggcacatt cgacttccct 660 gagttcctga cgatgatggc aagaaaaatg aattacacag acagtgaaga ggaaattaga 720 gaagcgttcc gcgtggcgga tagagcagg aatggctaca tcggcgcagc agagcttcgc 780 cacgcgatga cagacattgg agagaagtta acagatgagg aggttgatga aatgatcagg 840 gtagcagaca tcgatgggga tggtcaggta aactacgaag agtttgtaca aatgatgaca 900 gcgaagggtg gcggaggttc tgtcgactca tcacgtcgta agtggaataa ggcaggtcac 960 gcatggagag ctataggtcg gctgagctca cccgtggttt ccgagcggat gtaccccgag 1020 gacggagccc tgaagagcga gatcaagaag gggctgaggc tgaaggacgg cggccactac 1080 gccgccgagg tcaagaccac ctacaaggcc aagaagcccg tgcagctgcc cggcgcctac 1140 gtcgtcgaca tcaagttgga catcgtgtcc cacaacgagg actacaccat cgtggaacag 1200 tgcgaacgcg ccgagggccg ccactccacc ggcggcatgg tcgggctgta caag 1254 <210> 10 <211> 418 <212> PRT <213> Homo sapiens <400> 10 Met Gly Ser Leu Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile 1 5 10 15 Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly 20 25 30 His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Ala 35 40 45 Phe Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe 50 55 60 Ala Trp Asp Ile Leu Ser Pro Gln Phe Met Tyr Gly Ser Lys Ala Tyr 65 70 75 80 Ile Lys His Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu Ser Phe Pro 85 90 95 Glu Gly Phe Arg Trp Glu Arg Val Met Asn Phe Glu Asp Gly Gly Ile 100 105 110 Ile His Val Asn Gln Asp Ser Ser Leu Gln Asp Gly Val Phe Ile Tyr 115 120 125 Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly Pro Val Met 130 135 140 Gln Lys Lys Thr Met Gly Trp Glu Ala Thr Arg Asp Gln Leu Thr Glu 145 150 155 160 Glu Gln Ile Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe Asp Lys Asp 165 170 175 Gly Asn Gly Thr Met Thr Thr Lys Glu Leu Gly Thr Val Met Arg Ser 180 185 190 Leu Gly Gln Asn Pro Thr Glu Ala Glu Leu Gln Asp Met Ile Ser Glu 195 200 205 Val Asp Ala Asp Gly Asn Gly Thr Phe Asp Phe Pro Glu Phe Leu Thr 210 215 220 Met Met Ala Arg Lys Met Asn Tyr Thr Asp Ser Glu Glu Glu Ile Arg 225 230 235 240 Glu Ala Phe Arg Val Ala Asp Lys Asp Gly Asn Gly Tyr Ile Gly Ala 245 250 255 Ala Glu Leu Arg His Ala Met Thr Asp Ile Gly Glu Lys Leu Thr Asp 260 265 270 Glu Glu Val Asp Glu Met Ile Arg Val Ala Asp Ile Asp Gly Asp Gly 275 280 285 Gln Val Asn Tyr Glu Glu Phe Val Gln Met Met Thr Ala Lys Gly Gly 290 295 300 Gly Gly Ser Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His 305 310 315 320 Ala Trp Arg Ala Ile Gly Arg Leu Ser Ser Pro Val Val Ser Glu Arg 325 330 335 Met Tyr Pro Glu Asp Gly Ala Leu Lys Ser Glu Ile Lys Lys Gly Leu 340 345 350 Arg Leu Lys Asp Gly Gly His Tyr Ala Ala Glu Val Lys Thr Thr Tyr 355 360 365 Lys Ala Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Val Val Asp Ile 370 375 380 Lys Leu Asp Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln 385 390 395 400 Cys Glu Arg Ala Glu Gly Arg His Ser Thr Gly Gly Met Val Gly Leu 405 410 415 Tyr Lys <210> 11 <211> 1245 <212> DNA <213> Homo sapiens <400> 11 atggtgagca agggcgagga ggataacatg gccatcatca aggagttcat gcgcttcaag 60 gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga gggcgagggc 120 cgcccctacg aggcctttca gaccgctaag ctgaaggtga ccaagggtgg ccccctgccc 180 ttcgcctggg acatcctgtc ccttcagttc atgtacggct ccaaggccta cattaagcac 240 ccagccgaca tccccgacta cttcaagctg tccttccccg agggcttcag gtgggagcgc 300 gtgatgatct tcgaggacgg cggcattatt cacgttaacc aggactcctc cctgcaggac 360 ggcgtattca tctacaaggt gaagctgcgc ggcaccaact tccccccccga cggccccgta 420 480 gcagagttta aagaggcttt ctccctattt gacaaggacg gggatgggac gatgacaacc 540 aaggagctgg ggacggtgtt gcggtctctg gggcagaacc ccacagaagc agagctgcag 600 gacatgatca atgaagtaga tgccgacggt gacggcacat tcgacttccc tgagttcctg 660 acgatgatgg caaggaaaaat gaatgactca gacagtgaag aggaattag agaagcgttc 720 cgcgtggcgg ataaggacgg caatggctac atcggcgcag cagagcttcg ccacgcgatg 780 840 atcgatgggg atggtcaggt aaactacgaa gagtttgtac aaatgatgac agcgaagggt 900 ggcggaggtt ctgtcgactc atcacgtcgt aagtggata aggcaggtca cgcatggaga 960 gctataggtc ggctgagctc acgttgggtt tccgagtgga tgtaccccga ggacggcgcc 1020 ctgaagagcg tgatcagga ggggttgagg ctgaggacg gcggccacta cgccgccgag 1080 gtcaggacca cctacaaggc caaaagccc gtgcagctgc ccggcgccta catcgtcgac 1140 atcaagttgg acatcgtgtc ccacaacgag gactacacca tcgtggaaca gtgcgaacgc 1200 gccgaggggcc gccactccac cggcggcatg gacgagctgt acag 1245 <210> 12 <211> 415 <212> PRT <213> Homo sapiens <400> 12 Met Will Be Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe 1 5 10 15 Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe 20 25 30 Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Ala Phe Gln Thr 35 40 45 Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp 50 55 60 Leu Ser Leu Gln Phe Met Tyr Gly Ser Lys Ala Tyr Ile Lys His 65 70 75 80 Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu Ser Phe Pro Glu Gly Phe 85 90 95 Arg Trp Glu Arg Val Met Ile Phe Glu Asp Gly Gly Ile Ile His Val 100 105 110 Asn Gln Asp Ser Ser Leu Gln Asp Gly Val Phe Ile Tyr Lys Val Lys 115 120 125 Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly Pro Val Met Gln Lys Lys 130 135 140 Thr Met Gly Trp Glu Pro Thr Arg Asp Gln Leu Thr Glu Glu Gln Ile 145 150 155 160 Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe Asp Lys Asp Gly Asp Gly 165 170 175 Thr Met Thr Thr Lys Glu Leu Gly Thr Val Leu Arg Ser Leu Gly Gln 180 185 190 Asn Pro Thr Glu Ala Glu Leu Gln Asp Met Ile Asn Glu Val Asp Ala 195 200 205 Asp Gly Asp Gly Thr Phe Asp Phe Pro Glu Phe Leu Thr Met Met Ala 210 215 220 Arg Lys Met Asn Asp Ser Asp Ser Glu Glu Glu Ile Arg Glu Ala Phe 225 230 235 240 Arg Val Ala Asp Lys Asp Gly Asn Gly Tyr Ile Gly Ala Ala Glu Leu 245 250 255 Arg His Ala Met Thr Asp Ile Gly Glu Lys Leu Thr Asp Glu Glu Val 260 265 270 Asp Glu Met Ile Arg Val Ala Asp Ile Asp Gly Asp Gly Gln Val Asn 275 280 285 Tyr Glu Glu Phe Val Gln Met Met Thr Ala Lys Gly Gly Gly Gly Ser 290 295 300 Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His Ala Trp Arg 305 310 315 320 Ala Ile Gly Arg Leu Ser Ser Arg Trp Val Ser Glu Trp Met Tyr Pro 325 330 335 Glu Asp Gly Ala Leu Lys Ser Val Ile Lys Glu Gly Leu Arg Leu Lys 340 345 350 Asp Gly Gly His Tyr Ala Ala Glu Val Arg Thr Thr Tyr Lys Ala Lys 355 360 365 Lys Pro Val Gln Leu Pro Gly Ala Tyr Ile Val Asp Ile Lys Leu Asp 370 375 380 Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Cys Glu Arg 385 390 395 400 Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys 405 410 415 <210> 13 <211> 1245 <212> DNA <213> Homo sapiens <400> 13 atggtgagca agggcgagga ggataacatg gccatcatca aggagttcat gcgcttcaag 60 gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga gggcgagggc 120 cgcccctacg aggcctttca gaccgctaag ctgaaggtga ccaagggtgg ccccctgccc 180 ttcgcctggg acatcctgtc ccttcagttc atgtacggct ccaaggccta cattaagcac 240 ccagccgaca tccccgacta cttcaagctg tccttccccg agggcttcag gtgggagcgc 300 gtgatgatct tcgaggacgg cggcattatt cacgttaacc aggactcctc cctgcaggac 360 ggcgtattca tctacaaggt gaagctgcgc ggcaccaact tcccccccga cggccccgta 420 atgcagaaga agaccatggg ctgggagcct acgcgtgacc aactgactga agagcagatc 480 gcagagttta aagaggcttt ctccctattt gacaaggacg ggaatgggac gatgacaacc 540 aaggagctgg ggacggtgtt gcggtctctg gggcagaacc ccacagaagc agagctgcag 600 gacatgatca atgaagtaga tgccgacggt aacggcacat tcgacttccc tgagttcctg 660 acgatgatgg caaggaaaaat gaatgactca gacagtgaag aggaattag agaagcgttc 720 cgcgtggcgg ataaggacgg caatggctac atcggcgcag cagagcttcg ccacgcgatg 780 840 atcgatgggg atggtcaggt aaactacgaa gagtttgtac aaatgatgac agcgaagggt 900 ggcggaggtt ctgtcgactc atcacgtcgt aagtggata aggcaggtca cgcatggaga 960 gctataggtc ggctgagctc acgttgggtt tccgagtgga tgtaccccga ggacggcgcc 1020 ctgaagagcg tgatcaagga ggggttgagg ctgaagggacg gcggccacta cgccgccgag 1080 gtcaggacca cctacaaggc caaaaagccc gtgcagctgc ccggcgccta catcgtcgac 1140 atcaagttgg acatcgtgtc ccacaacgag gactacacca tcgtggaaca gtgcgaacgc 1200 gccgagggcc gccactccac cggcggcatg gacgagctgt acaag 1245 <210> 14 <211> 415 <212> PRT <213> Homo sapiens <400> 14 Met Val Ser Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe 1 5 10 15 Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe 20 25 30 Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Ala Phe Gln Thr 35 40 45 Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp 50 55 60 Ile Leu Ser Leu Gln Phe Met Tyr Gly Ser Lys Ala Tyr Ile Lys His 65 70 75 80 Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu Ser Phe Pro Glu Gly Phe 85 90 95 Arg Trp Glu Arg Val Met Ile Phe Glu Asp Gly Gly Ile Ile His Val 100 105 110 Asn Gln Asp Ser Ser Leu Gln Asp Gly Val Phe Ile Tyr Lys Val Lys 115 120 125 Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly Pro Val Met Gln Lys Lys 130 135 140 Thr Met Gly Trp Glu Pro Thr Arg Asp Gln Leu Thr Glu Glu Gln Ile 145 150 155 160 Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe Asp Lys Asp Gly Asn Gly 165 170 175 Thr Met Thr Thr Lys Glu Leu Gly Thr Val Leu Arg Ser Leu Gly Gln 180 185 190 Asn Pro Thr Glu Ala Glu Leu Gln Asp Met Ile Asn Glu Val Asp Ala 195 200 205 Asp Gly Asn Gly Thr Phe Asp Phe Pro Glu Phe Leu Thr Met Met Ala 210 215 220 Arg Lys Met Asn Asp Ser Asp Ser Glu Glu Glu Ile Arg Glu Ala Phe 225 230 235 240 Arg Val Ala Asp Lys Asp Gly Asn Gly Tyr Ile Gly Ala Ala Glu Leu 245 250 255 Arg His Ala Met Thr Asp Ile Gly Glu Lys Leu Thr Asp Glu Glu Val 260 265 270 Asp Glu Met Ile Arg Val Ala Asp Ile Asp Gly Asp Gly Gln Val Asn 275 280 285 Tyr Glu Glu Phe Val Gln Met Met Thr Ala Lys Gly Gly Gly Gly Ser 290 295 300 Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His Ala Trp Arg 305 310 315 320 Ala Ile Gly Arg Leu Ser Ser Arg Trp Val Ser Glu Trp Met Tyr Pro 325 330 335 Glu Asp Gly Ala Leu Lys Ser Val Ile Lys Glu Gly Leu Arg Leu Lys 340 345 350 Asp Gly Gly His Tyr Ala Ala Glu Val Arg Thr Thr Tyr Lys Ala Lys 355 360 365 Lys Pro Val Gln Leu Pro Gly Ala Tyr Ile Val Asp Ile Lys Leu Asp 370 375 380 Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Cys Glu Arg 385 390 395 400 Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys 405 410 415 <210> 15 <211> 1251 <212> DNA <213> Homo sapiens <400> 15 atggttgact cttcacgtcg taagtggaat aaggcaggtc acgcagtcag agctataggt 60 cggctgagct cacgttgggt ttccgagtgg atgtaccccg aggacggcgc cctgaagagc 120 gtgatcaag aggggttgag gctgaggac ggcggccact acggccgccga ggtcaggacc 180 acctacaagg ccaaaaagcc cgtgcagctg cccggcgcct acatcgtcga catcaagttg 240 gatacgtgt cccacaacga ggactacacc atcgtggac agtgcgaacg cgccgagggc 300 cgccacccca ccggcggcat gtcggggctg tacaagggag gtacaggcgg gagtctggtg 360 agcaagggcg aggaggataa catggccatc atcaggagt tcatgcgctt caggtgcac 420 atggaggct ccgtgaacgg ccacgagttc gagatcgagg gcgagggcga gggccgcccc 480 tacgaggcct ttcagaccgc tagctgaag gtgaccagg gtggccccct gcccttcgcc 540 tgggacatcc tgtccctca gttcatgtac ggctccagg cctacattaa gcaccagcc 600 gataccccg actactca gctgtccttc cccgaggggct tcaggtggga gcgcgtgatg 660 atcttcgagg acggcggcat tattcacgtt aaccaggact cctccctgca ggacggcgta 720 ttcatctaca aggtgaagct gcgcggcacc aacttccccc ccgacggccc cgtaatgcag 780 aagaagacca tgggctggga gcctacgcgt gaccactga ctgaagagca gatcgcagaa 840 tttaaagagg ctttctccct atttgacaag gacggggatg ggacaataac aaccaaggat 900 ctggggacgg tgctgcggtc tctggggcag aacccacag aagcagagct ccaggacatg 960 atcaatgaag tagatgccga cggtaatggc acaatcgact tccctgatt cctgacaatg 1020 atggcaagaaaatgaaaga cacacacagt gagagaaa ttcgcgaagc gttccgtgtg 1080 tgggatagg atggcaatgg ctacatctct gcagcagacc tcgccacgt gatgacaaac 1140 cttggagaga agttaacaga tgaagaggtt gatgaatga tcagggagc agatacgat 1200 ggagaaggtc aggtaacta cgaagagtttt gtacaatga tgacagcgaa g 1251 <210> 16 <211> 417 <212> PRT <213> Homo sapiens <400> 16 Met Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His Ala Val 1 5 10 15 Arg Ala Ile Gly Arg Leu Ser Arg Trp Val Ser Glu Trp Met Tyr 20 25 30 Pro Glu Asp Gly Ala Leu Lys Ser Val Ile Lys Glu Gly Leu Arg Leu 35 40 45 Lys Asp Gly Gly His Tyr Ala Ala Glu Val Arg Thr Thr Tyr Lys Ala 50 55 60 Lys Lys Pro Val Gln Leu Pro Gly Ala Tyr Ile Val Asp Ile Lys Leu 65 70 75 80 Asp Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Cys Glu 85 90 95 Arg Ala Glu Gly Arg His Pro Thr Gly Gly Met Val Gly Leu Tyr Lys 100 105 110 Gly Gly Thr Gly Gly Ser Leu Val Ser Lys Gly Glu Glu Asp Asn Met 115 120 125 Ala Ile Ile Lys Glu Phe Met Arg Phe Lys Val His Met Glu Gly Ser 130 135 140 Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro 145 150 155 160 Tyr Glu Ala Phe Gln Thr Ala Lys Leu Lys Val Thr Lys Gly Gly Pro 165 170 175 Leu Pro Phe Ala Trp Asp Ile Leu Ser Leu Gln Phe Met Tyr Gly Ser 180 185 190 Lys Ala Tyr Ile Lys His Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu 195 200 205 Ser Phe Pro Glu Gly Phe Arg Trp Glu Arg Val Met Ile Phe Glu Asp 210 215 220 Gly Gly Ile Ile His Val Asn Gln Asp Ser Ser Leu Gln Asp Gly Val 225 230 235 240 Phe Ile Tyr Lys Val Lys Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly 245 250 255 Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu Pro Thr Arg Asp Gln 260 265 270 Leu Thr Glu Glu Gln Ile Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe 275 280 285 Asp Lys Asp Gly Asp Gly Thr Ile Thr Thr Lys Asp Leu Gly Thr Val 290 295 300 Leu Arg Ser Leu Gly Gln Asn Pro Thr Glu Ala Glu Leu Gln Asp Met 305 310 315 320 Ile Asn Glu Val Asp Ala Asp Gly Asn Gly Thr Ile Asp Phe Pro Asp 325 330 335 Phe Leu Thr Met Met Ala Arg Lys Met Lys Asp Thr Asp Ser Glu Glu 340 345 350 Glu Ile Arg Glu Ala Phe Arg Val Trp Asp Lys Asp Gly Asn Gly Tyr 355 360 365 Ile Ser Ala Ala Asp Leu Arg His Val Met Thr Asn Leu Gly Glu Lys 370 375 380 Leu Thr Asp Glu Glu Val Asp Glu Met Ile Arg Glu Ala Asp Ile Asp 385 390 395 400 Gly Glu Gly Gln Val Asn Tyr Glu Glu Phe Val Gln Met Met Thr Ala 405 410 415 Lys <210> 17 <211> 1245 <212> DNA <213> Homo sapiens <400> 17 atggtgagca agggcgagga ggataacatg gccatcatca aggagttcat gcgcttcaag 60 gtgcacatgg agggctccgt gaacggccac gagttcgaga tcgagggcga gggcgagggc 120 cgcccctacg aggcctttca gaccgctaag ctgaaggtga ccaagggtgg ccccctgccc 180 ttcgcctggg acatcctgtc ccttcagttc atgtacggct ccaaggccta cattaagcac 240 ccagccgaca tccccgacta cttcaagctg tccttccccg agggcttcag gtgggagcgc 300 gtgatgatct tcgaggacgg cggcattatt cacgttaacc aggactcctc cctgcaggac 360 ggcgtattca tctacaaggt gaagctgcgc ggcaccaact tccccccccga cggccccgta 420 atgcagaaga agaccatggg ctgggagcct actcgggacc aactgactga agagcagatc 480 gcagaattta aagaggcttt ctccctattt gacaaggacg gggatgggac aataacaacc 540 areatctgg ggacggtgct gcggtctctg gggcagaacc ccacagaagc agagctccag 600 gacatgatca atgaagtaga tgccgacggt aatggcacaa tcgacttccc tgatttcctg 660 acaatgatgg caaaaaaat gaagacaca gacagtgaag aagaaattcg cgaagcgttc 720 cgtgtgtggg ataaggatgg caatggctac atctctgcag cagaccttcg ccacgtgatg 780 840 atcgatggag aaggtcaggt aaactagaa gagtttgtac aaatgatgac agcgaagggt 900 ggcggaggtt ctgtcgactc atcacgtcgt aagtggata aggcaggtca cgcagtcaga 960 gctataggtc ggctgagctc acgttgggtt tccgagtgga tgtaccccga ggacggcgcc 1020 ctgaagagcg tgatcaagga ggggttgagg ctgaagggacg gcggccacta cgccgccgag 1080 gtcaggacca cctacaaggc caaaagccc gtgcagctgc ccggcgccta catcgtcgac 1140 atcaagttgg acatcgtgtc ccacaacgag gactacacca tcgtggaaca gtgcgaacgc 1200 gccgaggggcc gccactccac cggcggcatg gacgagctgt acag 1245 <210> 18 <211> 415 <212> PRT <213> Homo sapiens <400> 18 Met Will Be Lys Gly Glu Glu Asp Asn Met Ala Ile Ile Lys Glu Phe 1 5 10 15 Met Arg Phe Lys Val His Met Glu Gly Ser Val Asn Gly His Glu Phe 20 25 30 Glu Ile Glu Gly Glu Gly Glu Gly Arg Pro Tyr Glu Ala Phe Gln Thr 35 40 45 Ala Lys Leu Lys Val Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp 50 55 60 Leu Ser Leu Gln Phe Met Tyr Gly Ser Lys Ala Tyr Ile Lys His 65 70 75 80 Pro Ala Asp Ile Pro Asp Tyr Phe Lys Leu Ser Phe Pro Glu Gly Phe 85 90 95 Arg Trp Glu Arg Val Met Ile Phe Glu Asp Gly Gly Ile Ile His Val 100 105 110 Asn Gln Asp Ser Ser Leu Gln Asp Gly Val Phe Ile Tyr Lys Val Lys 115 120 125 Leu Arg Gly Thr Asn Phe Pro Pro Asp Gly Pro Val Met Gln Lys Lys 130 135 140 Thr Met Gly Trp Glu Pro Thr Arg Asp Gln Leu Thr Glu Glu Gln Ile 145 150 155 160 Ala Glu Phe Lys Glu Ala Phe Ser Leu Phe Asp Lys Asp Gly Asp Gly 165 170 175 Thr Ile Thr Thr Lys Asp Leu Gly Thr Val Leu Arg Ser Leu Gly Gln 180 185 190 Asn Pro Thr Glu Ala Glu Leu Gln Asp Met Ile Asn Glu Val Asp Ala 195 200 205 Asp Gly Asn Gly Thr Ile Asp Phe Pro Asp Phe Leu Thr Met Met Ala 210 215 220 Arg Lys Met Lys Asp Thr Asp Ser Glu Glu Glu Ile Arg Glu Ala Phe 225 230 235 240 Arg Val Trp Asp Lys Asp Gly Asn Gly Tyr Ile Ser Ala Ala Asp Leu 245 250 255 Arg His Val Met Thr Asn Leu Gly Glu Lys Leu Thr Asp Glu Glu Val 260 265 270 Asp Glu Met Ile Arg Glu Ala Asp Ile Asp Gly Glu Gly Gln Val Asn 275 280 285 Tyr Glu Glu Phe Val Gln Met Met Thr Ala Lys Gly Gly Gly Gly Ser 290 295 300 Val Asp Ser Ser Arg Arg Lys Trp Asn Lys Ala Gly His Ala Val Arg 305 310 315 320 Ala Ile Gly Arg Leu Ser Ser Arg Trp Val Ser Glu Trp Met Tyr Pro 325 330 335 Glu Asp Gly Ala Leu Lys Ser Val Ile Lys Glu Gly Leu Arg Leu Lys 340 345 350 Asp Gly Gly His Tyr Ala Ala Glu Val Arg Thr Thr Tyr Lys Ala Lys 355 360 365 Lys Pro Val Gln Leu Pro Gly Ala Tyr Ile Val Asp Ile Lys Leu Asp 370 375 380 Ile Val Ser His Asn Glu Asp Tyr Thr Ile Val Glu Gln Cys Glu Arg 385 390 395 400 Ala Glu Gly Arg His Ser Thr Gly Gly Met Asp Glu Leu Tyr Lys 405 410 415 <210> 19 <211> 17 <212> PRT <213> Homo sapiens <400> 19 Met Leu Leu Pro Val Pro Leu Leu Leu Gly Leu Leu Gly Ala Ala Ala 1 5 10 15 Asp <210> 20 <211> 38 <212> DNA <213> Homo sapiens <400> 20 gatcggatcc aaccatggtg agcaagggcg aggaggat 38 <210> 21 <211> 34 <212> DNA <213> Homo sapiens <400> 21 gatcaagctt ttacttgtac agctcgtcca tgcc 34

Claims

1. Low affinity Ca 2+ Indicators are used in the preparation of Ca 2+ Application of reagents with varying levels, wherein The applications include: a. Obtaining a sample comprising cells engineered to express one or more low-affinity Ca 2+ An indicator, wherein the indicator is a polypeptide sequence selected from the group consisting of SEQ ID NOs: 12, 14, 16 and 18; b. exposing the cells to excitation light; and c. Detection of ER, SR, and / or mitochondrial Ca by visualization or imaging of cells 2+ Changes in levels.

2. The use according to claim 1, wherein: The sample includes cell culture, stem cells or mammalian plasma.

3. The use according to claim 2, wherein: The sample comprises a cell culture of a stable immortalized cell line.

4. The use according to claim 3, wherein: The cell culture comprises the HL1 cell line.

5. The use according to claim 1, wherein: The indicator is ratiometric.

6. The use according to any one of claims 1 to 5, wherein: The indicator is used in combination with another fluorescent indicator.

7. The use according to claim 6, wherein: The application uses a single wavelength two-color imaging approach.

8. The use according to claim 6, wherein: The another fluorescent indicator is a cytoplasmic calcium indicator.

9. The use according to any one of claims 1 to 5, wherein: The indicator is targeted to the organelle via an organelle-specific targeting sequence.

10. A low-affinity fluorescent Ca 2+ Peptides, wherein The low-affinity fluorescent Ca 2+ The polypeptide is an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 14, 16 and 18.

11. The polypeptide according to claim 10, wherein The polypeptide further comprises an organelle-specific targeting sequence, which is fused to the polypeptide so that the polypeptide is selectively expressed and retained in the organelle.

12. The polypeptide according to claim 11, wherein The organelle is ER, SR or mitochondria.

13. The polypeptide according to claim 11 or 12, wherein The polypeptide comprises the targeting sequence of SEQ ID NO:

19.

14. A polynucleotide encoding the polypeptide of any one of claims 10 to 13.

15. The polynucleotide according to claim 14, wherein The polynucleotide is a nucleic acid sequence selected from the group consisting of SEQ ID NO: 11, 13, 15 or 17.

16. The polynucleotide according to claim 14 or 15, wherein The polynucleotide further comprises a sequence encoding an organelle-specific targeting sequence.

17. The polynucleotide according to claim 16, wherein The organelle-specific targeting sequence is selected from SEQ ID NO:

19.

18. A vector, wherein The vector comprises the polynucleotide of any one of claims 14 to 17.

19. A host cell, wherein The host cell comprises the polynucleotide of any one of claims 14 to 17 or the vector of claim 18.

20. The host cell according to claim 19, wherein The host cell is a cardiomyocyte.

21. The host cell according to claim 19 or 20, wherein The host cells co-express another fluorescent calcium indicator.